

EULAR recommendations for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: 2013 update

Annals of the Rheumatic Diseases

73, 492-509

DOI: [10.1136/annrheumdis-2013-204573](https://doi.org/10.1136/annrheumdis-2013-204573)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Depression in Rheumatoid Arthritis and its relation to disease activity. <i>Pakistan Journal of Medical Sciences</i> , 1969, 31, 393-7.	0.3	32
2	How well can we compare different biologic agents for RA?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 247-248.	3.5	8
3	Golimumab: A Novel Anti-Tumor Necrosis Factor. <i>Biologics in Therapy</i> , 2013, 3, 83-107.	1.8	6
5	Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. <i>Croatian Medical Journal</i> , 2013, 54, 600-608.	0.2	39
6	Clinical Characteristics of Korean Rheumatoid Arthritis Patients with Indications for TNF- α Blocker. <i>Journal of Rheumatic Diseases</i> , 2014, 21, 1.	0.4	0
7	Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. <i>International Journal of Nanomedicine</i> , 2014, 9, 4911.	3.3	44
8	Tocilizumab in the treatment of rheumatoid arthritis and beyond. <i>Drug Design, Development and Therapy</i> , 2014, 8, 349.	2.0	70
9	Renal involvement in rheumatoid arthritis. <i>Reumatologia</i> , 2014, 5, 311-318.	0.5	1
10	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. <i>Biologics: Targets and Therapy</i> , 2014, 8, 141.	3.0	45
11	Pain in rheumatoid arthritis: a critical review. <i>Reumatismo</i> , 2014, 66, 18-27.	0.4	47
12	Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. <i>World Journal of Orthopedics</i> , 2014, 5, 516.	0.8	60
13	Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 313.	0.9	5
14	Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. <i>World Journal of Orthopedics</i> , 2014, 5, 504.	0.8	39
15	Methotrexate in rheumatoid arthritis: benefits, limitations and the emerging value of subcutaneous administration. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 345-351.	0.3	0
16	The future of biological agents in the treatment of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 475-486.	0.3	0
17	Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 843-854.	1.3	8
18	Moxibustion for treating rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Integrative Medicine</i> , 2014, 6, 621-630.	0.8	14
19	Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 393.	0.8	28

#	ARTICLE	IF	CITATIONS
20	Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 333.	0.8	49
21	Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 893-904.	1.4	12
22	Efficacy and safety of pateclizumab (anti-lymphotoxin- β) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). <i>Arthritis Research and Therapy</i> , 2014, 16, 467.	1.6	38
23	New EULAR guidelines for RA: a job well done. <i>Nature Reviews Rheumatology</i> , 2014, 10, 6-8.	3.5	3
25	Actualización en el tratamiento de la artritis reumatoide. <i>Medicine</i> , 2014, 11, 4112-4121.	0.0	1
26	Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	25
27	Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. <i>Patient Preference and Adherence</i> , 2014, 8, 1051.	0.8	5
28	Attenuation of Collagen-Induced Arthritis in Rat by Nicotinic Alpha7 Receptor Partial Agonist GTS-21. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	15
29	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. <i>BMJ Open</i> , 2014, 4, e005297-e005297.	0.8	19
30	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 327-339.	0.3	0
32	Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis. <i>Value in Health Regional Issues</i> , 2014, 4, 100-106.	0.5	16
33	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. <i>Journal of Rheumatology</i> , 2014, 41, 2370-2378.	1.0	9
34	Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2219-2220.	0.5	16
35	Are glucocorticoids harmful to bone in early rheumatoid arthritis?. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 50-54.	1.8	5
36	Receipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1447-1455.	1.5	19
37	IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1595-1597.	0.5	84
38	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625.	0.5	135
39	Psoriasis: to treat or to manage?. <i>Experimental Dermatology</i> , 2014, 23, 705-709.	1.4	70

#	ARTICLE	IF	CITATIONS
40	Vagus nerve stimulation: A new bioelectronics approach to treat rheumatoid arthritis?. Best Practice and Research in Clinical Rheumatology, 2014, 28, 625-635.	1.4	79
42	Rheumatoid arthritis: from palliation to remission in two decades. Clinical Medicine, 2014, 14, s50-s55.	0.8	7
43	Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?. Pharmacogenomics, 2014, 15, 1079-1090.	0.6	42
44	Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2014, 1, 31-44.	1.1	8
45	The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network. BMC Musculoskeletal Disorders, 2014, 15, 389.	0.8	12
46	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskeletal Disorders, 2014, 15, 449.	0.8	23
47	The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. BMC Medical Informatics and Decision Making, 2014, 14, 104.	1.5	33
48	Factors influencing rheumatologists's™ prescription of biological treatment in rheumatoid arthritis: an interview study. Implementation Science, 2014, 9, 153.	2.5	49
49	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, 430.	1.6	5
50	Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 159-168.	1.2	8
51	Mechanistic Insights Into the Link Between Inflammation and Cardiovascular Disease. Circulation: Cardiovascular Imaging, 2014, 7, 575-577.	1.3	6
52	New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis. Expert Review of Medical Devices, 2014, 11, 447-455.	1.4	17
53	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.5	11
54	Stem Cell Therapy in Autoimmune Rheumatic Diseases: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2014, 47, 244-257.	2.9	12
56	Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept. Case Reports in Rheumatology, 2014, 2014, 1-3.	0.2	4
57	Biosimilars: lights and shadows in rheumatology. Rheumatology Reports, 2014, 6, .	0.1	1
58	IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor ± inhibitors in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2014, 17, 872-877.	0.9	17
60	A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases, 2014, 73, 1027-1036.	0.5	60

#	ARTICLE	IF	CITATIONS
61	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.5	456
62	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
63	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	1.4	12
64	'Treat to target' for rheumatoid arthritis in 2014 - time tested triple therapy or logical Biologics?. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 1-3.	0.9	12
65	Certolizumab pegol in rheumatoid arthritis: current update. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 841-850.	1.4	10
66	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritis. <i>Advances in Therapy</i> , 2014, 31, 780-802.	1.3	2
67	Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs. <i>Drugs</i> , 2014, 74, 1091-1096.	4.9	10
68	Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 265-272.	0.6	17
69	Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?. <i>Immunologic Research</i> , 2014, 60, 289-310.	1.3	91
70	Multimorbidity and rheumatic conditions' enhancing the concept of comorbidity. <i>Nature Reviews Rheumatology</i> , 2014, 10, 252-256.	3.5	103
71	Triple terapia en la artritis reumatoide. <i>Reumatología Clínica</i> , 2014, 10, 275-277.	0.2	5
72	Triple therapy in rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 275-277.	0.2	1
73	Cytokine expression and cytokine-based T cell profiling in South Indian rheumatoid arthritis. <i>Immunobiology</i> , 2014, 219, 772-777.	0.8	8
74	Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1331-1339.	0.5	104
75	Oral or subcutaneous methotrexate for rheumatoid arthritis?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 578-579.	3.5	3
76	Toxidermie survenant sous tocilizumab au cours de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 512-513.	0.0	0
77	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	0.8	115
78	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 303-312.	0.0	10

#	ARTICLE	IF	CITATIONS
79	Novel Treatments with Small Molecules in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 443.	2.1	27
80	Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2014, 36, 1074-1086.	1.1	68
81	Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. <i>Rheumatology</i> , 2014, 53, 2110-2118.	0.9	122
82	Randomized Controlled Trial Comparing 2 Different Starting Doses of Methotrexate in Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2014, 36, 1005-1015.	1.1	9
83	Safety issues of biologics in pregnant patients with rheumatic diseases. <i>Annals of the New York Academy of Sciences</i> , 2014, 1317, 32-38.	1.8	45
84	Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 979-999.	1.9	39
85	Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. <i>Drugs</i> , 2014, 74, 1379-1410.	4.9	87
86	Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 803-809.	0.5	123
87	The issue of bioavailability of oral low dose methotrexate: should we choose only 10â€¦mg of MTX a week in conjunction with anti-TNF therapy?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e50-e50.	0.5	1
88	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an â€œanchorâ€•drug?. <i>Autoimmunity Reviews</i> , 2014, 13, 1102-1108.	2.5	70
90	Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 1239-1246.	1.0	9
91	Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 623-629.	1.0	15
92	Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. <i>Clinical Rheumatology</i> , 2014, 33, 1061-1066.	1.0	28
93	The â€œDirty Little Secretâ€•Exposed in the 2013 EULAR Recommendations for Rheumatoid Arthritis Therapy. <i>Clinical Therapeutics</i> , 2014, 36, 1114-1116.	1.1	3
94	Comparative effectiveness of cycling of tumor necrosis factor-Î± (TNF-Î±) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-Î± inhibitor using a Bayesian approach. <i>Archives of Pharmacal Research</i> , 2014, 37, 662-670.	2.7	33
95	The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1049-1057.	1.3	35
96	The Burden of Disease in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2014, 32, 841-851.	1.7	129
97	Glucocorticoid treatment in rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1575-1583.	0.9	26

#	ARTICLE	IF	CITATIONS
98	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 32-40.	1.8	24
99	Time Trends in Glucocorticoid Use in Rheumatoid Arthritis: Results From a Population-Based Inception Cohort, 1980-1994 Versus 1995-2007. <i>Arthritis Care and Research</i> , 2014, 66, 1482-1488.	1.5	30
100	Methotrexate for treating rheumatoid arthritis. <i>The Cochrane Library</i> , 2014, 2014, CD000957.	1.5	134
101	Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. <i>Autoimmunity Reviews</i> , 2014, 13, 873-879.	2.5	71
102	A Paradigm Shift in Rheumatoid Arthritis over the Past Decade. <i>Internal Medicine</i> , 2014, 53, 1895-1903.	0.3	20
105	The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, S1.	1.6	22
106	New insights into the impact of neuro-inflammation in rheumatoid arthritis. <i>Frontiers in Neuroscience</i> , 2014, 8, 357.	1.4	48
107	Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. <i>BMJ Open</i> , 2014, 4, e006058.	0.8	16
108	The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects. <i>Arthritis Research and Therapy</i> , 2014, 16, S2.	1.6	94
109	Circadian rhythms in rheumatology - a glucocorticoid perspective. <i>Arthritis Research and Therapy</i> , 2014, 16, S3.	1.6	55
110	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. , 2014, , CD007649.		14
111	Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 151-160.	1.5	15
112	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week 112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1627-1636.	1.5	13
113	Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1656-1663.	1.5	32
114	Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation. <i>Arthritis and Rheumatology</i> , 2015, 67, 2661-2672.	2.9	18
115	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. <i>Arthritis and Rheumatology</i> , 2015, 67, 3104-3112.	2.9	21
116	Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. <i>Clinical and Experimental Dental Research</i> , 2015, 1, 63-73.	0.8	31
117	I. Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 2110-2117.	0.0	0

#	ARTICLE	IF	CITATIONS
118	Modulation of Autoimmunity and Atherosclerosisâ€”â€” Common Targets and Promising Translational Approaches Against Disease â€”. <i>Circulation Journal</i> , 2015, 79, 924-933.	0.7	38
120	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015, 1, e000155-e000155.	1.8	34
121	Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2015, 9s1, CCRPM.S23288.	0.5	24
122	Glucocorticoids: bad or safe for the bones?. <i>RMD Open</i> , 2015, 1, e000050.	1.8	8
123	Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment. <i>RMD Open</i> , 2015, 1, e000018.	1.8	4
124	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000019-e000019.	1.8	90
125	Organizing Pneumonia in Rheumatoid Arthritis Patients: A Case-Based Review. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2015, 9s1, CCRPM.S23327.	0.5	14
126	Biosimilars: what do patients need to consider?. <i>RMD Open</i> , 2015, 1, e000141.	1.8	16
127	Response to: â€”Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR studyâ€™ by Sanmartiet al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e43-e43.	0.5	0
128	Rhabdomyolysis Secondary to Physical Activity and Simultaneous Electrostimulation. A Case Report. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2015, 11, 262-263.	0.2	5
130	Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 334-349.	0.6	6
131	Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace. <i>Drugs - Real World Outcomes</i> , 2015, 2, 205-215.	0.7	4
133	Comparison of two different folic acid doses with methotrexate â€” a randomized controlled trial (FOLVARI Study). <i>Arthritis Research and Therapy</i> , 2015, 17, 156.	1.6	28
134	Response to â€”Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™. <i>Arthritis Research and Therapy</i> , 2015, 17, 166.	1.6	1
135	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. <i>Arthritis Research and Therapy</i> , 2015, 17, 232.	1.6	88
136	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 206.	1.6	10
137	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	1.6	37
138	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S60-74.	1.0	39

#	ARTICLE	IF	CITATIONS
140	Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials. <i>Arthritis Care and Research</i> , 2015, 67, 1487-1495.	1.5	21
141	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 425-431.	0.3	0
142	Interstitial Lung Disease and Rheumatoid Arthritis: A Review. <i>Proceedings of Singapore Healthcare</i> , 2015, 24, 35-41.	0.2	4
143	A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 354.	0.8	31
144	Response to "Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis" authors' reply. <i>Arthritis Research and Therapy</i> , 2015, 17, 171.	1.6	0
145	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 245.	1.6	22
146	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. <i>Arthritis Research and Therapy</i> , 2015, 17, 281.	1.6	58
147	Continuously elevated serum matrix metalloproteinase-3 for 3-6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 289.	1.6	34
148	Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 322.	1.6	37
149	Patients' Considerations in the Decision-Making Process of Initiating Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015, 67, 956-964.	1.5	22
150	Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan. <i>Arthritis Care and Research</i> , 2015, 67, 1363-1370.	1.5	19
151	Antimalarial Drugs Alone May Still Have a Role in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 193-195.	0.5	3
152	Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. <i>Internal Medicine Journal</i> , 2015, 45, 1266-1273.	0.5	13
153	Tumor necrosis factor inhibitor-associated sinusitis. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2015, 33, 235-238.	0.0	0
154	SAT0184...Monitoring of EBV/CMV/VZV Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 721.2-722.	0.5	0
155	Adherence to Anti-Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 419-425.	0.5	39
156	Overall conceptual framework for studying the genetics of autoimmune diseases following vaccination: a regulatory perspective. <i>Biomarkers in Medicine</i> , 2015, 9, 1107-1120.	0.6	2
157	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 1345-1353.	1.5	72

#	ARTICLE	IF	CITATIONS
158	Superficial Tissue Necrosis Related to Methotrexate Injection in a Patient With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 370.	0.5	1
159	Proteomics in Rheumatoid Arthritis Research. <i>Immune Network</i> , 2015, 15, 177.	1.6	30
160	Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1325.	0.9	12
161	Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR. <i>Archives of Rheumatology</i> , 2015, 30, 271-284.	0.3	0
162	Factors Associated with the Initiation of Biologic Disease-Modifying Antirheumatic Drugs in Texas Medicaid Patients with Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 401-407.	0.5	21
163	Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2015, 9, 119.	3.0	11
164	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. <i>World Journal of Hepatology</i> , 2015, 7, 344.	0.8	61
165	Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure – results of the Polish survey in the context of EULAR recommendations. <i>Reumatologia</i> , 2015, 4, 200-206.	0.5	1
166	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. <i>Current Biomarker Findings</i> , 2015, , 69.	0.4	2
167	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 409-423.	0.5	86
168	Biologic monotherapy in the treatment of rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2015, 9, 35.	3.0	16
169	The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0119683.	1.1	75
170	Remission of Collagen-Induced Arthritis through Combination Therapy of Microfracture and Transplantation of Thermogel-Encapsulated Bone Marrow Mesenchymal Stem Cells. <i>PLoS ONE</i> , 2015, 10, e0120596.	1.1	22
171	Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0123392.	1.1	14
172	Management of rheumatoid arthritis in People's Republic of China – focus on tocilizumab and patient considerations. <i>International Journal of General Medicine</i> , 2015, 8, 187.	0.8	24
173	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	19
174	Polish Rheumatologists and Rheumatoid Arthritis Patients Differ in Their Opinions About Treatment Inefficacy. <i>Archives of Rheumatology</i> , 2015, 30, 238-243.	0.3	2
175	Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study. <i>Journal of Rheumatology</i> , 2015, 42, 599-607.	1.0	7

#	ARTICLE	IF	CITATIONS
176	Predictors of response to TNF- α antagonist therapy in Chinese rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1203-1210.	1.0	24
177	Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 \hat{e} .year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 341-346.	0.5	22
178	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 1099-1104.	1.0	39
179	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	2.9	213
180	Blockade of co-stimulation in chronic inflammatory diseases. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 23-27.	0.5	4
181	Rheumatoid Arthritis \hat{e} ” Anti-TNF. <i>International Immunopharmacology</i> , 2015, 27, 180-184.	1.7	31
182	Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 843-850.	0.5	86
183	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. <i>Modern Rheumatology</i> , 2015, 25, 11-20.	0.9	11
184	Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 109.	0.8	2
185	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	1.6	53
186	Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 883-889.	0.5	18
187	Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1408-1414.	0.9	98
188	Inflammatory signaling induced bone loss. <i>Bone</i> , 2015, 80, 143-149.	1.4	29
189	Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 28-34.	1.6	34
190	Advances in the treatment of polyarticular juvenile idiopathic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 505-510.	2.0	30
191	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	2.9	146
192	Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 543-549.	1.4	18
193	Co-morbidity index in rheumatoid arthritis: time to think. <i>Clinical Rheumatology</i> , 2015, 34, 1995-2000.	1.0	18

#	ARTICLE	IF	CITATIONS
194	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2015, 54, 1200-1209.	0.9	64
195	Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom. <i>Rheumatology</i> , 2015, 54, kev268.	0.9	11
196	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	1.6	53
197	Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden. <i>Journal of Rheumatology</i> , 2015, 42, 2247-2254.	1.0	13
198	Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs). <i>SpringerPlus</i> , 2015, 4, 462.	1.2	9
199	How does established rheumatoid arthritis develop, and are there possibilities for prevention?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 527-542.	1.4	15
201	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and Ninja Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	1.0	14
202	A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders. <i>European Journal of General Practice</i> , 2015, 21, 231-237.	0.9	18
203	Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-24.	1.3	7
204	The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 124.	1.6	14
205	Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 512-521.	0.7	0
206	Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 399-404.	1.6	3
207	Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 806-812.	0.5	154
208	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 115-122.	1.3	4
209	Toxidermia under treatment with tocilizumab for rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015, 82, 69-70.	0.8	4
210	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.5	10
211	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 3-9.	0.5	125
212	Inflammatory Arthritis in Clinical Practice. , 2015, , .		2

#	ARTICLE	IF	CITATIONS
213	High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. <i>Rheumatology International</i> , 2015, 35, 1377-1384.	1.5	30
214	Chronic Pain Syndromes, Mechanisms, and Current Treatments. <i>Progress in Molecular Biology and Translational Science</i> , 2015, 131, 565-611.	0.9	10
215	Etanercept Tapering in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2015, 372, 489-490.	13.9	1
216	Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. <i>Journal of the Neurological Sciences</i> , 2015, 349, 143-148.	0.3	32
217	Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015, 82, 25-30.	0.8	54
218	Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. <i>Joint Bone Spine</i> , 2015, 82, 13-17.	0.8	32
219	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	3.5	372
220	Methotrexate revisited: considerations for subcutaneous administration in RA. <i>Clinical Rheumatology</i> , 2015, 34, 201-205.	1.0	9
221	The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. <i>Rheumatology International</i> , 2015, 35, 1149-1161.	1.5	17
222	Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?. <i>Clinical Rheumatology</i> , 2015, 34, 1-8.	1.0	12
223	Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2015, 18, 366-375.	1.0	2
224	Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2015, 14, 517-527.	2.5	42
225	IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. <i>Archives of Pharmacal Research</i> , 2015, 38, 575-584.	2.7	162
226	Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. <i>Rheumatology</i> , 2015, 54, 1226-1235.	0.9	24
227	Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015, 25, 534-539.	0.9	24
228	Systemic Lentivirus-Mediated Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 as Gene Therapy for Collagen-Induced Arthritis. <i>Journal of Immunology</i> , 2015, 194, 76-83.	0.4	37
229	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2165-2174.	0.5	33
230	Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52. <i>Modern Rheumatology</i> , 2015, 25, 31-37.	0.9	16

#	ARTICLE	IF	CITATIONS
231	Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. <i>Modern Rheumatology</i> , 2015, 25, 251-256.	0.9	18
232	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. <i>Autoimmunity Reviews</i> , 2015, 14, 503-509.	2.5	150
233	Management of juvenile idiopathic arthritis: hitting the target. <i>Nature Reviews Rheumatology</i> , 2015, 11, 290-300.	3.5	91
234	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 564-568.	0.5	39
235	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
236	Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. <i>Clinical Rheumatology</i> , 2015, 34, 935-942.	1.0	19
237	Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases. , 2015, , 515-525.		0
238	Novel therapeutic targets in rheumatoid arthritis. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 189-195.	4.0	137
239	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2015, 67, 280-309.	7.1	266
240	A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 861-869.	1.0	12
242	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. <i>BMJ, The</i> , 2015, 350, h1046-h1046.	3.0	59
243	Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. <i>Rheumatology and Therapy</i> , 2015, 2, 85-96.	1.1	15
244	Managing unwanted immunogenicity of biologicals. <i>Autoimmunity Reviews</i> , 2015, 14, 569-574.	2.5	50
245	Fatigue: the heavy backpack of many rheumatoid arthritis patients. <i>Rheumatology</i> , 2015, 54, 962-963.	0.9	3
246	Analysis of patents on anti-rheumatoid arthritis therapies issued in China. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 909-930.	2.4	10
247	Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations. <i>Drugs and Aging</i> , 2015, 32, 515-524.	1.3	22
248	Consideraciones a las recomendaciones terapéuticas para la artritis reumatoide. <i>Reumatología Clínica</i> , 2015, 11, 193-195.	0.2	4
249	Consensus on the Use of Methotrexate Beyond the Clinical Recommendation: Adjusted Dose and Pharmacogenetics. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 261-262.	0.2	0

#	ARTICLE	IF	CITATIONS
250	Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. <i>Rheumatology</i> , 2015, 54, 854-859.	0.9	9
252	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
253	Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1037-1044.	0.5	190
254	Optimizing treatment in paediatric rheumatology—lessons from oncology. <i>Nature Reviews Rheumatology</i> , 2015, 11, 493-499.	3.5	4
255	Advances in the management of rheumatoid arthritis. <i>Scottish Medical Journal</i> , 2015, 60, 108-114.	0.7	5
256	Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. <i>Arthritis and Rheumatology</i> , 2015, 67, 1474-1480.	2.9	50
257	Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. <i>Inflammation Research</i> , 2015, 64, 647-659.	1.6	14
258	Recommendations for the management of autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1636-1644.	0.5	239
259	The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 851-858.	0.7	8
260	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. <i>BMJ</i> , 2015, 350, h1269-h1269.	3.0	98
261	Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1890-1896.	0.9	34
262	Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. <i>Cytokine</i> , 2015, 75, 222-227.	1.4	16
263	Considerations on treatment recommendations for rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 193-195.	0.2	1
264	Remission in rheumatoid arthritis: is it all the same?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 575-586.	1.3	11
265	Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. <i>Rheumatology</i> , 2015, 54, 1664-1672.	0.9	72
266	Special Issue on Glucocorticoid Therapy in Rheumatic Diseases: Introduction. <i>NeuroImmunoModulation</i> , 2015, 22, 3-5.	0.9	6
267	IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients. <i>Clinical Immunology</i> , 2015, 158, 174-182.	1.4	21
268	Consenso sobre el uso de metotrexato más allá de la recomendación clínica: dosis ajustada y farmacogenética. <i>Reumatología Clínica</i> , 2015, 11, 261-262.	0.2	0

#	ARTICLE	IF	CITATIONS
269	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	8.2	14
270	Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. <i>Expert Review of Vaccines</i> , 2015, 14, 891-908.	2.0	30
271	The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1886-1889.	0.5	21
272	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	1.0	22
273	Factors Associated With Sustained Remission in Patients With Rheumatoid Arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2015, 11, 237-241.	0.2	3
274	Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab. <i>Rheumatology</i> , 2015, 54, 743-744.	0.9	4
276	Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change. <i>Quality of Life Research</i> , 2015, 24, 607-616.	1.5	7
278	Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab. <i>Rheumatology and Therapy</i> , 2015, 2, 17-31.	1.1	4
279	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	1.6	49
280	Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 285-294.	3.3	41
281	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356.	3.5	91
282	Arthritis Clinical Trials at a Crossroad. <i>Journal of Rheumatology</i> , 2015, 42, 14-17.	1.0	4
283	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 97.	1.6	38
284	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , 2015, 42, 799-809.	1.0	39
285	Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks. <i>Journal of Rheumatology</i> , 2015, 42, 786-793.	1.0	23
286	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , 2015, 161, 2-10.	1.4	45
287	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Lancet, The</i> , 2015, 386, 258-265.	6.3	487
288	A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence. <i>Analyst, The</i> , 2015, 140, 1981-1987.	1.7	23

#	ARTICLE	IF	CITATIONS
289	The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy. <i>Current Rheumatology Reports</i> , 2015, 17, 513.	2.1	48
290	Temperature-responsive polymeric nanospheres containing methotrexate and gold nanoparticles: A multi-drug system for theranostic in rheumatoid arthritis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 133, 378-387.	2.5	69
291	Brief Report: Leucineâ€Rich Î± ₂ â€Glycoprotein as a Potential Biomarker for Joint Inflammation During Antiâ€Interleukinâ€6 Biologic Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2056-2060.	2.9	71
292	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	0.9	13
293	Combination conventional DMARDs compared to biologicals. <i>Current Opinion in Rheumatology</i> , 2015, 27, 183-188.	2.0	13
294	Glucocorticoid safety for treating rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 839-844.	1.0	9
295	New insights into the measurement of disease activity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 268-272.	2.0	7
296	Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient. <i>Journal of Rheumatology</i> , 2015, 42, 580-584.	1.0	47
297	Oral Low-Dose Glucocorticoids Should Be Included in Any Recommendation for the Use of Non-Biologic and Biologic Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 104-111.	0.9	12
298	Effects of TNFÎ± inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 525-532.	1.0	15
299	Conventional DMARDs in axial spondyloarthritis: wishfulâ€rather than rationalâ€thinking!. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 951-953.	0.5	7
300	Biological agents and respiratory infections: Causative mechanisms and practice management. <i>Respiratory Investigation</i> , 2015, 53, 185-200.	0.9	14
302	Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 751-760.	1.3	14
303	Education for patients with rheumatoid arthritis in Latin America and the Caribbean. <i>Clinical Rheumatology</i> , 2015, 34, 45-49.	1.0	12
304	Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. <i>Clinical Therapeutics</i> , 2015, 37, 1662-1676.e2.	1.1	20
305	Prediction of Response to Therapy for Autoimmune/Inflammatory Diseases Using an Activated Macrophage-Targeted Radioimaging Agent. <i>Molecular Pharmaceutics</i> , 2015, 12, 3547-3555.	2.3	15
306	Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. <i>Clinical Rheumatology</i> , 2015, 34, 1787-1793.	1.0	25
307	Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study. <i>Rheumatology International</i> , 2015, 35, 1825-1836.	1.5	8

#	ARTICLE	IF	CITATIONS
308	Remission in SLE: closing in on the target. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2103-2106.	0.5	19
309	Treatment of rheumatoid arthritis: Unraveling the conundrum. <i>Journal of Autoimmunity</i> , 2015, 65, 1-18.	3.0	99
310	<scp>APLAR</scp> rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 685-713.	0.9	109
311	Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2015, 37, 1454-1465.	1.1	28
312	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. <i>Rheumatology</i> , 2015, 54, kev249.	0.9	10
313	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. <i>Reumatolog�a Cl�nica (English Edition)</i> , 2015, 11, 279-294.	0.2	38
314	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , 2015, 1, e000057.	1.8	98
315	Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. <i>RMD Open</i> , 2015, 1, e000147.	1.8	11
316	The Budget Impact of Biosimilar Infliximab (Remsima�) for the Treatment of Autoimmune Diseases in Five European Countries. <i>Advances in Therapy</i> , 2015, 32, 742-756.	1.3	127
317	Patient-centred care in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 643-663.	1.4	99
318	Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 67-77.	0.3	17
319	Concomitant Methotrexate Protects Against Total Knee Arthroplasty in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2015, 42, 2255-2260.	1.0	14
320	Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?. <i>Arthritis Research and Therapy</i> , 2015, 17, 181.	1.6	59
321	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis. <i>Therapeutic Delivery</i> , 2015, 6, 283-295.	1.2	11
322	Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. <i>RMD Open</i> , 2015, 1, e000078-e000078.	1.8	15
323	The Past versus the Present, 1980-2004: Reduction of Mean Initial Low-Dose, Long-Term Glucocorticoid Therapy in Rheumatoid Arthritis from 10.3 to 3.6 mg/Day, Concomitant with Early Methotrexate, with Long-Term Effectiveness and Safety of Less than 5 mg/Day. <i>NeuroImmunoModulation</i> , 2015, 22, 89-103.	0.9	12
324	Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. <i>Rheumatology</i> , 2015, 54, kev216.	0.9	34
325	Access to an optimal treatment. Current situation. <i>Clinical Rheumatology</i> , 2015, 34, 59-66.	1.0	18

#	ARTICLE	IF	CITATIONS
326	Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA). <i>Medical Hypotheses</i> , 2015, 85, 433-440.	0.8	5
327	Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 35-43.	0.5	94
328	A Study of Multiple Causes of Death in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2221-2228.	1.0	40
329	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
330	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.5	130
331	Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1676-1683.	0.5	21
332	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
333	Addressing comorbidities in systemic inflammatory disorders. <i>Nature Reviews Rheumatology</i> , 2015, 11, 689-691.	3.5	2
335	Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2066-2070.	1.0	6
336	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
339	Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 512-521.	0.8	10
340	The role of cytokines in the pathogenesis of rheumatoid arthritis – Practical and potential application of cytokines as biomarkers and targets of personalized therapy. <i>Cytokine</i> , 2015, 76, 527-536.	1.4	150
341	Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready?. <i>Clinical Rheumatology</i> , 2015, 34, 79-93.	1.0	5
342	Rheumatoid arthritis in Latin America. Important challenges to be solved. <i>Clinical Rheumatology</i> , 2015, 34, 1-3.	1.0	20
343	Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. <i>International Immunopharmacology</i> , 2015, 28, 802-807.	1.7	45
344	Autophagy protects meniscal cells from glucocorticoids-induced apoptosis via inositol trisphosphate receptor signaling. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 1176-1186.	2.2	23
345	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. <i>Current Rheumatology Reports</i> , 2015, 17, 65.	2.1	16
346	Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study. <i>Journal of Rheumatology</i> , 2015, 42, 1603-1609.	1.0	12

#	ARTICLE	IF	CITATIONS
347	The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2015, 16, 1615-1625.	0.9	13
348	Actualizaci3n 2014 del Documento de Consenso de la Sociedad Espa3ola de Reumatolog3a sobre el uso de terapias biol3gicas en la artritis reumatoide. Reumatolog3a Cl3nica, 2015, 11, 279-294.	0.2	89
349	How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. BMJ, The, 2015, 351, h3658.	3.0	11
350	Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scandinavian Journal of Rheumatology, 2015, 44, 449-455.	0.6	18
351	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Research and Therapy, 2015, 17, 193.	1.6	7
352	Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis. Journal of Ultrasound in Medicine, 2015, 34, 1621-1630.	0.8	24
353	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.5	220
354	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2015, 74, 1808-1817.	0.5	74
356	Management of perioperative tumour necrosis factor inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology, 2016, 55, kev364.	0.9	41
358	Factores asociados a remisi3n sostenida en pacientes con artritis reumatoide. Reumatolog3a Cl3nica, 2015, 11, 237-241.	0.2	4
359	Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. Joint Bone Spine, 2015, 82, 451-454.	0.8	9
360	De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?. Best Practice and Research in Clinical Rheumatology, 2015, 29, 550-565.	1.4	45
361	Severe low back pain in patients with rheumatoid arthritis is associated with Disease Activity Score but not with radiological findings on plain X-rays. Modern Rheumatology, 2015, 25, 56-61.	0.9	17
362	Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. Rheumatology, 2015, 54, 1033-1038.	0.9	10
363	Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Annals of the Rheumatic Diseases, 2015, 74, 381-388.	0.5	142
364	Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology, 2015, 54, 113-120.	0.9	22
365	Combining biologics with methotrexate in psoriasis: a systematic review. British Journal of Dermatology, 2015, 172, 1676-1680.	1.4	10
366	Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 307-316.	1.5	32

#	ARTICLE	IF	CITATIONS
367	Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1150-1155.	0.5	41
368	Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). <i>Rheumatology</i> , 2015, 54, 798-807.	0.9	42
369	Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1233-1240.	0.5	61
370	Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. <i>Clinical Rheumatology</i> , 2015, 34, 949-956.	1.0	21
371	Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e12-e12.	0.5	132
372	Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future. <i>European Journal of Pharmacology</i> , 2015, 747, 200-205.	1.7	16
373	Initial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light in Early Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 51-56.	0.9	12
374	Circadian Use of Glucocorticoids in Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 33-39.	0.9	17
375	Impact of Medication Withdrawal Method on Flare-Free Survival in Patients with Juvenile Idiopathic Arthritis on Combination Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 658-666.	1.5	37
376	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 27-34.	0.5	106
377	Asymptomatic colitis induced by low-dose methotrexate. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217771.	0.2	5
378	AB0329...Ultrasound 7 versus Ultrasound12 in Monitoring The Response To Adalimumab in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1013.3-1014.	0.5	0
379	Impact of Patient Education on the Satisfaction of Rheumatoid Arthritis Patients: A Randomized Trial of Nurse-led Versus Medical Doctor-led Education. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 109.	0.4	3
380	Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study. <i>Archives of Rheumatology</i> , 2016, 31, 127-132.	0.3	0
381	Comparative analysis of educational needs of patients with rheumatic diseases selected based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT). <i>Reumatologia</i> , 2016, 4, 153-160.	0.5	4
382	Developments in the Treatment of Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis. , 0, , .		0
383	The Therapeutic Effect of Sauchinone on Inflammatory Arthritis in Mice. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 161.	0.4	0
384	Japanese physicians’ preferences for decision making in rheumatoid arthritis treatment. <i>Patient Preference and Adherence</i> , 2016, 10, 107.	0.8	9

#	ARTICLE	IF	CITATIONS
385	Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2217-2228.	0.8	64
386	Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 22-34.	0.3	8
387	The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study. <i>Reumatismo</i> , 2016, 68, 188-194.	0.4	2
388	Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 209-218.	0.5	29
389	Nocebo effects in practice: methotrexate myths and misconceptions. <i>Medical Journal of Australia</i> , 2016, 205, 440-442.	0.8	5
390	Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1763-1776.	0.9	11
391	Effective abatacept therapy in a hemodialysis patient with rheumatoid arthritis. <i>Nihon Toseki Igakkai Zasshi</i> , 2016, 49, 593-597.	0.2	1
392	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. <i>Journal of Korean Medical Science</i> , 2016, 31, 1907.	1.1	7
393	Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case-Control Study. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S38442.	0.3	3
394	Posttranslational Modifications and the Immunogenicity of Biotherapeutics. <i>Journal of Immunology Research</i> , 2016, 2016, 1-15.	0.9	93
395	Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It?. <i>Case Reports in Rheumatology</i> , 2016, 2016, 1-5.	0.2	1
396	The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	10
397	Rheumatoid polyarthritis suspected in an HIV patient with scleritis, peripheral ulcerative keratitis, and anterior uveitis. <i>International Medical Case Reports Journal</i> , 2016, 9, 19.	0.3	2
398	Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. <i>Patient Preference and Adherence</i> , 2016, 10, 1079.	0.8	23
399	Secukinumab for rheumatology: development and its potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2069-2080.	2.0	37
400	Personalized medicine in rheumatology. <i>Reumatologia</i> , 2016, 54, 177-186.	0.5	14
401	Rate of Proven Rheumatic Diseases in a Large Collective of Referrals to an Outpatient Rheumatology Clinic under Routine Conditions. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S40361.	0.3	12
402	Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1457-1471.	0.5	33

#	ARTICLE	IF	CITATIONS
403	FRI0192â€¦Clinical Importance of Anti-Drug and Serum Drug Level Testing in Rheumatoid Arthritis Patients Treated with Etanercept. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499.3-500.	0.5	0
404	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 159.	1.6	38
405	A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 190.	1.6	24
406	Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs. <i>Arthritis Research and Therapy</i> , 2016, 18, 252.	1.6	18
407	Ten years of publicly funded biological diseaseâ€¦modifying antirheumatic drugs in Australia. <i>Medical Journal of Australia</i> , 2016, 204, 64-68.	0.8	14
408	Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. <i>PLoS ONE</i> , 2016, 11, e0154744.	1.1	45
409	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166691.	1.1	8
410	Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. <i>Patient Preference and Adherence</i> , 2016, 10, 1101.	0.8	26
412	Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies. <i>Patient Related Outcome Measures</i> , 2016, 7, 1.	0.7	25
413	Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice. <i>Medicine (United States)</i> , 2016, 95, e3476.	0.4	13
414	New concepts of clinical trials in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 316-322.	2.0	5
415	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohnâ€™s disease in Argentina, Brazil, Colombia, and Mexico. <i>Journal of Medical Economics</i> , 2016, 19, 1187-1199.	1.0	7
416	Treat-to-target as an approach in inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 297-302.	2.0	45
417	Targeted ILâ€4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis. <i>European Journal of Immunology</i> , 2016, 46, 1246-1257.	1.6	16
418	The development of a questionnaire to evaluate rheumatoid arthritis patient's knowledge about methotrexate. <i>Journal of Clinical Nursing</i> , 2016, 25, 682-689.	1.4	10
419	Agreement of Physicians and Nurses Performing Tender and Swollen Joint Counts in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 30-34.	0.5	4
420	Brief Report: Estimating Disease Activity Using Multiâ€Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 2083-2089.	2.9	42
421	Utility of <sc>J</sc>apanese oriental medicine for the alternative target in the treating rheumatoid arthritis to target: 2014 recommendations update. <i>Traditional & Kampo Medicine</i> , 2016, 3, 162-166.	0.2	0

#	ARTICLE	IF	CITATIONS
422	Bone Mineral Density in Patients With Rheumatoid Arthritis and 4-Year Follow-up Results. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 71-74.	0.5	11
423	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	2.9	70
424	Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 927-935.	1.5	10
425	Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry. <i>Arthritis Care and Research</i> , 2016, 68, 914-921.	1.5	5
426	Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 844-851.	0.9	41
427	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016, 2, e000323.	1.8	13
428	Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1595-1598.	0.5	15
429	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1336-1342.	0.5	55
430	Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2016, 18, 211.	1.6	44
431	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.5	160
432	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	1.8	57
433	Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area. <i>Scientific Reports</i> , 2016, 6, 29443.	1.6	38
434	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1763-1769.	0.5	70
435	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. <i>RMD Open</i> , 2016, 2, e000237.	1.8	52
436	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.5	81
437	Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2119-2123.	0.5	29
438	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. <i>RMD Open</i> , 2016, 2, e000171.	1.8	40
439	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1043-1050.	0.5	167

#	ARTICLE	IF	CITATIONS
440	Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1902-1908.	0.5	93
441	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1081-1091.	0.5	152
442	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.5	26
443	Correlation between clinical activity measured by DAS-28 and ultrasound in patients with rheumatoid arthritis. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2016, 23, 159-169.	0.1	0
444	Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1265-1267.	0.5	0
445	Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. <i>RMD Open</i> , 2016, 2, e000265.	1.8	20
446	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	1.8	38
447	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 55-61.	1.0	20
448	Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. <i>Rheumatology</i> , 2017, 56, kew442.	0.9	49
449	Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 1959-1967.	0.9	7
450	Preservation of cartilage and bone architecture is the most important aspect for maintaining functionality in longstanding experimental arthritis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1329-1338.	1.2	39
451	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 3-10.	1.0	15
452	Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe. <i>Rheumatology and Therapy</i> , 2016, 3, 77-89.	1.1	19
453	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016, 2, e000228.	1.8	15
454	Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. <i>Rheumatology and Therapy</i> , 2016, 3, 245-256.	1.1	29
455	Therapeutic implications of autoantibodies in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000009.	1.8	39
456	Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 22387.	1.6	15
457	Glucocorticoids and chronotherapy in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000203.	1.8	51

#	ARTICLE	IF	CITATIONS
458	Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia. <i>International Journal of Clinical Practice</i> , 2016, 70, 506-511.	0.8	11
459	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
460	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	0.6	120
461	Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naïve Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 699-706.	1.0	17
462	Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. <i>Rheumatology International</i> , 2016, 36, 613-625.	1.5	60
463	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 81-87.	1.6	18
464	Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2016, 38, 646-654.	1.1	19
465	Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases. <i>Clinical Therapeutics</i> , 2016, 38, 1451-1463.	1.1	12
466	Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1177-1183.	0.8	33
467	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. <i>Lancet</i> , 2016, 388, 239-247.	6.3	95
468	Retraso diagnóstico y terapéutico de la artritis reumatoide y su relación con dispositivos asistenciales en Catalunya. <i>Estudio AUDIT. Reumatología Clínica</i> , 2016, 12, 146-150.	0.2	13
469	Diagnostic and Therapeutic Delay of Rheumatoid Arthritis and its Relationship With Health Care Devices in Catalonia. The AUDIT Study. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 146-150.	0.2	7
470	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. <i>Drug Safety</i> , 2016, 39, 823-840.	1.4	28
471	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 61.	0.8	8
472	Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. <i>Advances in Therapy</i> , 2016, 33, 369-378.	1.3	75
473	Discoveries of conventional synthetic disease modifying anti-rheumatic drugs – Serendipity or flawless reasoning?. <i>Indian Journal of Rheumatology</i> , 2016, 11, 32-38.	0.2	3
474	Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. <i>Drugs and Aging</i> , 2016, 33, 97-107.	1.3	44
475	Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate. <i>Journal of Rheumatology</i> , 2016, 43, 731-737.	1.0	26

#	ARTICLE	IF	CITATIONS
476	Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts Attenuates Joint Inflammation in Collagen Antibody-Induced Arthritis. <i>American Journal of Pathology</i> , 2016, 186, 1293-1301.	1.9	14
477	The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016, 12, 255-256.	3.5	2
478	Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 146.	0.8	43
479	Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2016, 38, 1205-1216.	1.1	10
480	Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden. <i>Journal of Rheumatology</i> , 2016, 43, 1017-1023.	1.0	17
481	Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2016, 35, 301-306.	1.7	22
482	Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF- κ B and MAPK pathways. <i>International Immunopharmacology</i> , 2016, 35, 294-300.	1.7	40
483	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	0.9	20
484	Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 836-843.	0.9	9
485	Rheumatoid arthritis. <i>Lancet, The</i> , 2016, 388, 2023-2038.	6.3	2,989
486	Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study. <i>Pharmacology</i> , 2016, 98, 73-78.	0.9	2
487	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1063-1067.	1.0	29
488	Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. <i>Clinical Therapeutics</i> , 2016, 38, 1359-1375.e1.	1.1	19
489	Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 448-455.	0.6	23
490	Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. <i>Journal of Medical Economics</i> , 2016, 19, 812-821.	1.0	9
491	Treatment of rheumatoid arthritis (RA) in India—how and by whom: results from a speciality clinic—use of low-dose methotrexate (MTX) was inexplicably suboptimal. <i>Clinical Rheumatology</i> , 2016, 35, 2163-2173.	1.0	4
492	Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. <i>Joint Bone Spine</i> , 2016, 83, 412-415.	0.8	17
493	Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2016, 35, 1659-1668.	1.0	23

#	ARTICLE	IF	CITATIONS
494	Efficacy and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 1130-1135.	1.0	16
495	Pre-treatment antinuclear antibody positivity, therapeutic efficacy and persistence of biologics in rheumatoid arthritis. <i>Romanian Journal of Laboratory Medicine</i> , 2016, 24, 212-222.	0.1	0
496	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD010227.	1.5	64
497	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
498	Screening Tool for Older Persons™ Appropriate Prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on "Guidelines for medical treatment and its safety in the elderly". <i>Geriatrics and Gerontology International</i> , 2016, 16, 983-1001.	0.7	125
499	Pharmacogenetics of methotrexate in rheumatoid arthritis: A systematic review. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2016, 23, 102-114.	0.1	2
500	Cyclosporine Reduces Sclerosis in Morphea: A Retrospective Study in 12 Patients and a Literature Review. <i>Dermatology</i> , 2016, 232, 503-510.	0.9	13
501	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1428-1437.	0.5	232
502	AmÃ©lioration des rÃ©sultats rapportÃ©s par les patients atteints de polyarthrite rhumatoÃ¯de traitÃ©s par rituximab: Ã©valuation ouverte de 175 patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 457-460.	0.0	0
503	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016, 44, 113-118.	0.4	12
504	Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 272-278.	1.6	8
505	Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis. <i>Transfusion and Apheresis Science</i> , 2016, 55, 225-232.	0.5	5
506	Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 405.	0.8	23
508	Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. <i>BioDrugs</i> , 2016, 30, 607-617.	2.2	30
509	Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 246.	0.8	13
510	Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. <i>Clinical Rheumatology</i> , 2016, 35, 2915-2923.	1.0	25
511	Interleukin 27. , 2016, , 749-759.		0
512	Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. <i>Rheumatology</i> , 2016, 55, 1803-1811.	0.9	23

#	ARTICLE	IF	CITATIONS
513	Combination therapy with biologic agents in rheumatic diseases: current and future prospects. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 192-202.	1.2	32
514	Review of head-to-head study designs in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 279-285.	1.6	18
515	Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. <i>Rheumatology</i> , 2016, 55, 1959-1968.	0.9	59
516	Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1303-1309.	1.4	21
517	Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses. <i>International Immunopharmacology</i> , 2016, 39, 236-245.	1.7	3
518	Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2016, 186, 157-163.	1.1	36
519	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 107-118.	1.2	21
520	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	1.5	27
521	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 113-123.	1.1	19
522	Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. <i>BioDrugs</i> , 2016, 30, 371-378.	2.2	13
523	Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?. <i>Clinical Rheumatology</i> , 2016, 35, 3053-3056.	1.0	1
524	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	0.9	22
526	Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis. <i>Inflammopharmacology</i> , 2016, 24, 189-196.	1.9	32
527	Management of rheumatoid arthritis: Review of current guidelines. <i>Journal of Arthroscopy and Joint Surgery</i> , 2016, 3, 45-50.	0.3	10
528	Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 358.	0.8	8
529	Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009. <i>Current Medical Research and Opinion</i> , 2016, 32, 2029-2037.	0.9	19
530	Treatment of rheumatoid arthritis. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 176-180.	0.1	3
531	Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. <i>Clinical Therapeutics</i> , 2016, 38, 2628-2641.e5.	1.1	44

#	ARTICLE	IF	CITATIONS
532	PROMs and Patient Education. , 2016, , 389-403.		2
533	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 539-549.	0.6	13
534	Toward Electronic Health Recording: Evaluation of Electronic Patient-reported Outcome Measures System for Remote Monitoring of Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 2106-2112.	1.0	39
535	Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. <i>BioDrugs</i> , 2016, 30, 469-480.	2.2	22
537	Magnetic Resonance Imaging Bone Edema at Enrollment Predicts Rapid Radiographic Progression in Patients with Early RA: Results from the Nagasaki University Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2016, 43, 1278-1284.	1.0	14
538	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. <i>Current Rheumatology Reports</i> , 2016, 18, 50.	2.1	27
539	Effective transdermal delivery of methotrexate through nanostructured lipid carriers in an experimentally induced arthritis model. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 147, 17-24.	2.5	67
540	Emerging Therapies for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2016, 3, 31-42.	1.1	26
541	Validation of disease activity indices using the 28 joint counts in systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1849-1858.	0.9	18
542	Efficacy and safety of an anti-CD20 monoclonal antibody (Redituxâ„¢) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. <i>Clinical Rheumatology</i> , 2016, 35, 1931-1935.	1.0	6
544	Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00254.	1.1	11
545	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016, 388, 2763-2774.	6.3	144
546	EXXELERATE: a negative trial with importance for clinical practice. <i>Lancet, The</i> , 2016, 388, 2718-2719.	6.3	1
547	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). <i>The Cochrane Library</i> , 2016, 2016, CD012437.	1.5	27
548	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	1.5	5
549	Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 460.	0.8	9
550	Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. <i>Journal of International Medical Research</i> , 2016, 44, 90-94.	0.4	8
551	Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 790-795.	1.0	1

#	ARTICLE	IF	CITATIONS
552	Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice. <i>Scientific Reports</i> , 2016, 5, 18288.	1.6	14
553	Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice. <i>Scientific Reports</i> , 2016, 6, 35804.	1.6	44
554	Idiopathic Thrombocytopenic Purpura. , 2016, , 595-604.		0
555	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
556	Folypolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 35615.	1.6	35
557	Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1355-1359.	1.9	21
558	A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 351.	0.8	11
559	Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources. <i>Rheumatology and Therapy</i> , 2016, 3, 337-352.	1.1	27
560	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 1997-2009.	1.0	78
561	Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence. <i>BioDrugs</i> , 2016, 30, 489-523.	2.2	32
562	Response to: "Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update" by Goswami et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e36-e36.	0.5	2
563	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. <i>BMJ, The</i> , 2016, 354, i4205.	3.0	200
564	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016, 2, e000263.	1.8	6
565	SAT0168...Clinical Remission Outcomes with Sarilumab plus Csds in Active, Moderate-To-Severe RA Patients with Inadequate Response To Tumor Necrosis Factor Inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 727.2-728.	0.5	0
566	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. <i>BMJ, The</i> , 2016, 353, i1777.	3.0	155
567	Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000241.	1.8	8
568	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016, 2, e000245.	1.8	15
569	Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists. <i>RMD Open</i> , 2016, 2, e000195.	1.8	8

#	ARTICLE	IF	CITATIONS
570	Age at natural menopause in women on long-term methotrexate therapy for rheumatoid arthritis. <i>Menopause</i> , 2016, 23, 1130-1138.	0.8	6
571	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 461.	0.8	22
572	The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database. <i>Rheumatology and Therapy</i> , 2016, 3, 167-177.	1.1	5
573	High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT). <i>Medicine (United States)</i> , 2016, 95, e3968.	0.4	22
574	Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases. <i>SAGE Open Medicine</i> , 2016, 4, 205031211665440.	0.7	17
575	Correlaci3n entre la actividad cl3nica por DAS-28 y ecograf3a en pacientes con artritis reumatoide. <i>Revista Colombiana De Reumatolog3a</i> , 2016, 23, 159-169.	0.0	0
576	Rheumatology Resources in a Region of Buenos Aires Province, Argentina. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 260-263.	0.5	3
577	Evaluating Adherence to a Treat-to-Target Protocol in Recent Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation. <i>Arthritis Care and Research</i> , 2016, 68, 446-453.	1.5	20
578	Use of Low-Literacy Decision Aid to Enhance Knowledge and Reduce Decisional Conflict Among a Diverse Population of Adults With Rheumatoid Arthritis: Results of a Pilot Study. <i>Arthritis Care and Research</i> , 2016, 68, 889-898.	1.5	40
579	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. <i>Arthritis Care and Research</i> , 2016, 68, 1478-1488.	1.5	54
580	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD012183.	1.5	51
581	The Use of Low-Dose Oral Glucocorticoids Was Minimized in the 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: Comment on the Article by Singh et al. <i>Arthritis Care and Research</i> , 2016, 68, 722-722.	1.5	3
582	Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2016, 68, 1767-1773.	1.5	81
583	The Use of Low-Dose Oral Glucocorticoids Was Minimized in the 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1314-1314.	2.9	4
584	Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1093-1102.	0.9	13
585	Prediction of radiographic progression in synovitis-positive joints on maximum intensity projection of magnetic resonance imaging in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 873-878.	1.0	6
586	Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1547-1558.	1.6	92
587	Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2345.	3.8	87

#	ARTICLE	IF	CITATIONS
588	Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. <i>Lancet</i> , The, 2016, 388, 343-355.	6.3	197
589	Beyond methotrexate monotherapy for early rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 309-310.	6.3	0
590	<i>KIR2DL2</i> and <i>KIR2DS2</i> as genetic markers to the methotrexate response in rheumatoid arthritis patients. <i>Immunopharmacology and Immunotoxicology</i> , 2016, 38, 303-309.	1.1	15
592	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , 2016, 3, 129-141.	1.1	3
593	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. <i>Rheumatology and Therapy</i> , 2016, 3, 103-115.	1.1	8
594	Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. <i>Biologicals</i> , 2016, 44, 257-266.	0.5	73
595	Rheumatoid arthritis at present. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 112-114.	0.1	0
597	Cost Analysis of Biologic Drugs in Rheumatoid Arthritis First Line Treatment After Methotrexate Failure According to Patients' Body Weight. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 123-129.	0.2	3
598	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 33.	0.8	2
599	Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 72.	1.6	11
600	Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 60.	1.6	23
601	Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. <i>Clinical Microbiology and Infection</i> , 2016, 22, 815.e1-815.e3.	2.8	33
603	Rheumatoide Arthritis (RA). <i>Wiener Klinische Wochenschrift Education</i> , 2016, 11, 1-10.	0.0	0
604	Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2016, 111, 264-271.	3.1	35
605	Unraveling Patient-Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study. <i>Arthritis Care and Research</i> , 2016, 68, 1278-1287.	1.5	45
606	Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 45-51.	0.5	165
607	The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 51-56.	0.9	8
608	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1003-1008.	0.5	56

#	ARTICLE	IF	CITATIONS
609	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
610	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 491-498.	0.9	80
611	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	1.4	22
612	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1065-1069.	1.0	7
613	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. <i>Rheumatology International</i> , 2016, 36, 685-695.	1.5	201
614	Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 171-178.	0.6	22
615	Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. <i>Advances in Therapy</i> , 2016, 33, 46-57.	1.3	21
616	Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2016, 17, 45-9.	0.6	11
617	Strategies for the optimal use of biologic agents in rheumatoid arthritis. , 2016, , 93-107.		0
618	Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada. <i>Journal of Rheumatology</i> , 2016, 43, 530-540.	1.0	63
619	Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis. <i>Clinical Rheumatology</i> , 2016, 35, 1153-1159.	1.0	8
620	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASPO15K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1057-1064.	0.5	125
621	A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model. <i>Reproductive Sciences</i> , 2016, 23, 662-669.	1.1	20
622	Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 103-114.	1.3	13
623	Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 656-662.	1.6	27
624	Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. <i>Clinical Rheumatology</i> , 2016, 35, 219-225.	1.0	3
625	Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 289-296.	2.0	23
626	Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2016, 43, 855-860.	1.0	59

#	ARTICLE	IF	CITATIONS
627	Advances in the Medical Treatment of RA: What Surgeons Need to Know. , 2016, , 3-11.		1
628	Farmacogenética del metotrexato en artritis reumatoide. Revisión sistemática. Revista Colombiana De Reumatología, 2016, 23, 102-114.	0.0	6
629	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. Rheumatology, 2016, 55, 1177-1187.	0.9	31
630	The influence of patient perceptions of disease on medication intensification in daily practice. Rheumatology, 2016, 55, 1938-1945.	0.9	9
631	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology, 2016, 55, 1217-1224.	0.9	31
632	Rheumatoid arthritis management of early disease. Current Opinion in Rheumatology, 2016, 28, 267-274.	2.0	12
633	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Modern Rheumatology, 2016, 26, 15-23.	0.9	53
634	Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis. Inflammation Research, 2016, 65, 347-354.	1.6	5
636	Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor- α therapy in clinical practice. Journal of the Formosan Medical Association, 2016, 115, 83-93.	0.8	6
637	Development of a Rheumatology-specific Patient Concerns Inventory and Its Use in the Rheumatology Outpatient Clinic Setting. Journal of Rheumatology, 2016, 43, 779-787.	1.0	9
638	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. Journal of Rheumatology, 2016, 43, 504-511.	1.0	110
639	Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study. Journal of Rheumatology, 2016, 43, 716-723.	1.0	23
640	Biosimilars: Rationale and current regulatory landscape. Seminars in Arthritis and Rheumatism, 2016, 45, S1-S10.	1.6	39
641	Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology, 2016, 55, 826-839.	0.9	81
642	ROUTINE—a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology, 2016, 55, 624-635.	0.9	35
643	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 319-326.	1.5	7
644	“The lesser of two evils” — views of persons with rheumatoid arthritis on medication adherence: a qualitative study. Psychology and Health, 2016, 31, 675-692.	1.2	19
645	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology, 2016, 26, 850-856.	0.9	14

#	ARTICLE	IF	CITATIONS
646	IL-1 receptor antagonist (IL-1Ra)-Fc ameliorate autoimmune arthritis by regulation of the Th17 cells/Treg balance and arthrogenic cytokine activation. <i>Immunology Letters</i> , 2016, 172, 56-66.	1.1	12
647	Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. <i>Vascular Pharmacology</i> , 2016, 81, 22-30.	1.0	21
648	Adaptive Response of T and B Cells in Atherosclerosis. <i>Circulation Research</i> , 2016, 118, 668-678.	2.0	209
649	Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. <i>Modern Rheumatology</i> , 2016, 26, 807-812.	0.9	8
650	An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 878-884.	0.9	3
651	Biosimilar DMARDs: What Does the Future Hold?. <i>Drugs</i> , 2016, 76, 629-637.	4.9	11
652	Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. <i>Experimental and Molecular Medicine</i> , 2016, 48, e211-e211.	3.2	30
653	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBcâ€“positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	1.0	49
654	Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 255-261.	0.6	42
655	Gist and verbatim communication concerning medication risks/benefits. <i>Patient Education and Counseling</i> , 2016, 99, 988-994.	1.0	7
656	Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. <i>Cytokine</i> , 2016, 78, 87-93.	1.4	37
657	Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. <i>Rheumatology</i> , 2016, 55, 143-148.	0.9	40
658	CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 417-425.	1.3	40
659	Safety and efficacy of intra-articular anti-tumor necrosis factor $\hat{\pm}$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
660	Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 201-211.	1.4	30
661	Iguratimod in combination with methotrexate in active rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 2016, 75, 828-833.	0.5	28
662	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	1.0	10
663	Modified intention-to-treat analysis did not bias trial results. <i>Journal of Clinical Epidemiology</i> , 2016, 72, 66-74.	2.4	39

#	ARTICLE	IF	CITATIONS
664	Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?. <i>Rheumatology</i> , 2016, 55, 197-198.	0.9	0
665	Small molecules with anti-inflammatory properties in clinical development. , 2016, 157, 163-187.		45
666	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1321-1327.	0.5	42
667	Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2016, 19, 101-112.	1.0	34
668	Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective. <i>Journal of Dermatological Treatment</i> , 2016, 27, 128-133.	1.1	5
669	Biologic efficacy optimization“a step towards personalized medicine. <i>Rheumatology</i> , 2016, 55, 780-788.	0.9	38
670	Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. <i>MAbs</i> , 2016, 8, 141-149.	2.6	82
671	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.5	94
672	Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 409-417.	0.7	7
673	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
674	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	1.5	10
675	Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1661-1666.	0.5	28
676	Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes. <i>Reumatología Clínica</i> , 2016, 12, 123-129.	0.2	5
677	Successful tocilizumab desensitization in an adult with juvenile idiopathic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 75-76.	0.6	8
678	Use of biologics in SLE: a review of the evidence from a clinical perspective. <i>Rheumatology</i> , 2016, 55, 775-779.	0.9	10
679	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1615-1621.	0.5	421
680	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	0.9	31
681	¹⁸ F-FDG and ¹⁸ F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 180-187.	0.9	31

#	ARTICLE	IF	CITATIONS
682	Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept. <i>Modern Rheumatology</i> , 2016, 26, 29-35.	0.9	9
683	Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 386-390.	1.6	37
684	Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1126-1132.	0.5	85
686	Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study. <i>Modern Rheumatology</i> , 2016, 26, 24-28.	0.9	6
687	Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 385-393.	0.6	27
688	Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. <i>Modern Rheumatology</i> , 2016, 26, 169-174.	0.9	14
689	Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 15-22.	0.7	8
690	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.5	146
691	Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual. <i>Reumatología Clínica</i> , 2017, 13, 78-84.	0.2	4
692	Biosimilars in rheumatology: understanding the rigor of their development. <i>Rheumatology</i> , 2017, 56, 187-197.	0.9	30
693	The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. <i>Modern Rheumatology</i> , 2017, 27, 42-49.	0.9	12
694	Clinical pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2017, 17, 412-418.	0.9	12
695	O anti-CCP não é um marcador de gravidade da artrite reumatoide estabelecida: um estudo de ressonância magnética. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 15-22.	0.8	4
696	A disintegrin and metalloproteinase (ADAM)-10 as a predictive factor for tocilizumab effectiveness in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2017, 27, 782-786.	0.9	5
697	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017, 7, 40473.	1.6	32
698	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	0.9	19
699	RAP-eL: rheumatoid arthritis e-learning for physiotherapists. <i>Journal of Physiotherapy</i> , 2017, 63, 61.	0.7	1
700	Impacto de variantes genéticas del transportador de membrana que une ATP B1, la aicar transformilasa/IMP ciclohidrolasa, la folilpoliglutamatosintetasa y la metilen-tetrahidrofolatorreductasa en la toxicidad de metotrexato. <i>Reumatología Clínica</i> , 2017, 13, 318-325.	0.2	6

#	ARTICLE	IF	CITATIONS
701	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	1.0	28
703	Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. <i>Clinical Drug Investigation</i> , 2017, 37, 375-386.	1.1	14
704	Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study. <i>Modern Rheumatology</i> , 2017, 27, 953-960.	0.9	8
705	Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score. <i>Modern Rheumatology</i> , 2017, 27, 938-945.	0.9	6
706	Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 975-982.	1.5	8
707	The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 289-302.	1.0	14
708	Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1143-1148.	1.0	26
709	IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. <i>Scientific Reports</i> , 2017, 7, 41143.	1.6	24
710	Monitoring total-body inflammation and damage in joints and entheses: the first follow-up study of whole-body magnetic resonance imaging in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 253-262.	0.6	15
711	Cardiac Diseases in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 227-263.	0.1	1
712	Cardiac Effects of Antirheumatic Drugs. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 489-529.	0.1	0
713	Integrating patients'™ perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan. <i>Modern Rheumatology</i> , 2017, 27, 924-929.	0.9	6
714	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1773-1781.	1.1	27
715	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83
716	Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1-year of the ACT-SOLO study. <i>RMD Open</i> , 2017, 3, e000340.	1.8	6
717	Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 511-520.	0.5	92
718	Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1797-1802.	0.5	52
719	Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator and Placebo-Controlled Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1144-1153.	2.9	144

#	ARTICLE	IF	CITATIONS
720	Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the <sc>PREDICT</sc> study. International Journal of Rheumatic Diseases, 2017, 20, 460-468.	0.9	17
721	Predictors of severe radiographic progression in patients with early rheumatoid arthritis: A Prospective observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 1437-1446.	0.9	10
722	2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 2017, 76, 948-959.	0.5	393
723	Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts. Current Rheumatology Reports, 2017, 19, 12.	2.1	6
724	No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis. RMD Open, 2017, 3, e000352.	1.8	19
725	Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?. European Journal of Hospital Pharmacy, 2017, 24, 85-90.	0.5	8
726	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. The Cochrane Library, 2017, 2017, CD012591.	1.5	44
727	Peripheral Ulcerative Keratitis. Essentials in Ophthalmology, 2017, , .	0.0	4
728	Nanotherapeutics relieve rheumatoid arthritis. Journal of Controlled Release, 2017, 252, 108-124.	4.8	170
729	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Annals of the Rheumatic Diseases, 2017, 76, 126-132.	0.5	33
730	Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. Clinical Rheumatology, 2017, 36, 1013-1022.	1.0	20
731	Relationship between clinical evaluation and ultrasound assessment of rheumatoid arthritis patients using a 12 joint score. International Journal of Rheumatic Diseases, 2017, 20, 852-858.	0.9	4
732	Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatology International, 2017, 37, 1053-1064.	1.5	14
733	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1058-1072.	1.9	43
734	Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) – A prospective, multicenter, single arm pilot clinical trial. Modern Rheumatology, 2017, 27, 930-937.	0.9	6
735	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open, 2017, 3, e000404.	1.8	43
736	Improved survival in rheumatoid arthritis: a general population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 408-413.	0.5	85
737	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.5	1,220

#	ARTICLE	IF	CITATIONS
738	Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. <i>Scientific Reports</i> , 2017, 7, 42191.	1.6	36
739	Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. <i>RMD Open</i> , 2017, 3, e000363.	1.8	70
740	Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 7.	0.4	3
741	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. <i>Rheumatology and Therapy</i> , 2017, 4, 1-24.	1.1	34
742	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. <i>RMD Open</i> , 2017, 3, e000382.	1.8	71
743	Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study. <i>Rheumatology International</i> , 2017, 37, 891-896.	1.5	15
744	Steroids and Autoimmunity. <i>Frontiers of Hormone Research</i> , 2017, 48, 121-132.	1.0	29
745	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
746	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1228-1236.	0.5	70
747	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.5	36
748	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor+methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000371.	1.8	26
749	Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 33.	1.6	42
750	R�le de lâ�chographie dans le suivi de la polyarthrite rhumato�de. <i>Revue Du Rhumatisme (Edition) Tj ETQq0,0,0 rgBT /Overlock 1</i>	0,0	0
751	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
752	Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response. <i>Modern Rheumatology</i> , 2017, 27, 961-966.	0.9	6
753	Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study. <i>Acta Clinica Belgica</i> , 2017, 72, 424-428.	0.5	1
754	Dosing down with biologic therapies: a systematic review and cliniciansâ€™ perspective. <i>Rheumatology</i> , 2017, 56, 1847-1856.	0.9	59
755	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2017, 44, 773-779.	1.0	3

#	ARTICLE	IF	CITATIONS
756	CTLA-4 expressed by FOXP3 ⁺ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis. <i>Immunology</i> , 2017, 152, 125-137.	2.0	18
757	S100-alarmins: potential therapeutic targets for arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 738-750.	1.5	38
758	Therapeutic effect of Cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation. <i>Biochemical Pharmacology</i> , 2017, 138, 119-129.	2.0	36
759	Glucocorticoids in rheumatoid arthritis: the picture is shaping up. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1785-1787.	0.5	20
760	An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions. <i>Journal of International Medical Research</i> , 2017, 45, 733-743.	0.4	11
761	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 5, CD012657.	1.5	47
763	Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. <i>Future Oncology</i> , 2017, 13, 17-29.	1.1	10
764	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. <i>Clinical Rheumatology</i> , 2017, 36, 1237-1245.	1.0	23
765	Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. <i>Rheumatology</i> , 2017, 56, 1367-1377.	0.9	29
766	High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients—A Preliminary Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 157-163.	1.0	13
767	Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1559-1565.	0.5	108
768	Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2017, 44, 981-987.	1.0	23
769	Effect of cardiorespiratory and strength exercises on disease activity in patients with inflammatory rheumatic diseases: a systematic review and meta-analysis. <i>British Journal of Sports Medicine</i> , 2017, 51, 1065-1072.	3.1	88
770	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. <i>Trials</i> , 2017, 18, 161.	0.7	19
771	Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment. <i>Arthritis Research and Therapy</i> , 2017, 19, 78.	1.6	7
772	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 791-798.	1.0	2
773	Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. <i>Clinical Rheumatology</i> , 2017, 36, 1-8.	1.0	25
774	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 241-250.	1.0	40

#	ARTICLE	IF	CITATIONS
775	Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. <i>Journal of Rheumatology</i> , 2017, 44, 142-146.	1.0	27
776	Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 147-153.	1.0	7
777	What the Rheumatologist Is Looking for and What the Radiologist Should Know in Imaging for Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , 2017, 55, 905-916.	0.9	7
778	Treatment of Rheumatoid Arthritis With Anti-“Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 1484-1494.	1.5	39
779	Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. <i>Rheumatology International</i> , 2017, 37, 1441-1452.	1.5	6
780	Golimumab: A Review in Inflammatory Arthritis. <i>BioDrugs</i> , 2017, 31, 263-274.	2.2	11
781	Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. <i>Rheumatology International</i> , 2017, 37, 1701-1708.	1.5	2
782	High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the <sc>TOMORROW</sc> study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 949-959.	0.9	9
783	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017, 8, 15877.	5.8	72
784	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. <i>Rheumatology International</i> , 2017, 37, 1111-1123.	1.5	10
785	Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. <i>Clinical Rheumatology</i> , 2017, 36, 1493-1500.	1.0	103
786	CT-P13 in the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 653-666.	1.3	1
787	Cyclocurcumin, a curcumin derivative, exhibits immune-modulating ability and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method. <i>International Journal of Molecular Medicine</i> , 2017, 39, 1164-1172.	1.8	26
788	Maintenance of remission with combination etanercept-“DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017, 37, 1469-1479.	1.5	16
789	Lack of association between <i>MTHFR</i> A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 526-540.	0.9	6
790	Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. <i>Journal of Internal Medicine</i> , 2017, 282, 64-75.	2.7	104
791	Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey. <i>Clinical Rheumatology</i> , 2017, 36, 1471-1478.	1.0	17
792	Abatacept: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2017, 77, 1221-1233.	4.9	143

#	ARTICLE	IF	CITATIONS
793	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. <i>BMJ Open</i> , 2017, 7, e016154.	0.8	16
794	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000410.	1.8	28
796	The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2017, 189, 12-20.	1.1	65
797	Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?. <i>Journal of Rheumatology</i> , 2017, 44, 732-739.	1.0	67
798	Two-year Efficacy of tocilizumab in Patients With Active Rheumatoid Arthritis in Clinical Practice. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 78-84.	0.2	2
799	Effect of methotrexate on bone and wound healing. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 535-545.	1.0	30
800	Improved disease activity with fosdagrocorat (<scp>PF</scp>â€04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 960-970.	0.9	27
801	Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. <i>Arthritis Research and Therapy</i> , 2017, 19, 68.	1.6	66
802	Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 425-431.	0.6	13
803	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1279-1284.	0.5	64
804	â€œNo evident disease activityâ€ The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1179-1187.	1.4	126
805	Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. <i>Arthritis Care and Research</i> , 2017, 69, 1467-1472.	1.5	24
806	Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?. <i>Rheumatology International</i> , 2017, 37, 905-913.	1.5	10
807	A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 1347-1356.	1.5	7
808	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 57-69.	1.1	11
809	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.5	131
811	Immunology proves a great success for treating systemic autoimmune diseases â€“ a perspective on immunopharmacology: IUPHAR Review 23. <i>British Journal of Pharmacology</i> , 2017, 174, 1875-1880.	2.7	8
812	Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. <i>Modern Rheumatology</i> , 2017, 27, 755-765.	0.9	28

#	ARTICLE	IF	CITATIONS
813	Meta-analysis of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1473-1483.	1.5	9
814	Living with persistent rheumatoid arthritis: a BARFOT study. <i>Journal of Clinical Nursing</i> , 2017, 26, 2646-2656.	1.4	20
815	Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 369-376.	1.5	17
816	Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. <i>Rheumatology</i> , 2017, 56, 68-76.	0.9	15
817	Official View on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017, 69, 1134-1141.	1.5	39
818	Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas. <i>Journal of Neurotrauma</i> , 2017, 34, 1996-2000.	1.7	6
819	Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. <i>Current Medical Research and Opinion</i> , 2017, 33, 657-666.	0.9	11
820	Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 15-22.	2.4	20
821	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. <i>Modern Rheumatology</i> , 2017, 27, 811-819.	0.9	10
822	Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 187-195.	1.9	32
823	Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial. <i>Joint Bone Spine</i> , 2017, 84, 577-581.	0.8	10
824	Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1510-1518.	1.5	102
825	Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1504-1509.	1.5	25
826	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017, 69, 953-963.	2.9	27
827	Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors. <i>Clinical Rheumatology</i> , 2017, 36, 941-946.	1.0	1
828	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	1.0	33
829	Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2017, 84, 563-570.	0.8	12
830	Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 891-897.	0.5	77

#	ARTICLE	IF	CITATIONS
831	Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1674-1683.	0.9	8
832	Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor- κ B expression in monocytes from patients with early rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000365.	1.8	18
833	Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2017, 44, 1794-1803.	1.0	33
834	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017, 3, e000465.	1.8	10
835	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. <i>Advances in Therapy</i> , 2017, 34, 2422-2435.	1.3	28
836	Arthroscopic Synovectomy of Wrist in Rheumatoid Arthritis. <i>Hand Clinics</i> , 2017, 33, 779-785.	0.4	14
837	Pain relieving and protective effects of Astragalus hydroalcoholic extract in rat arthritis models. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1858-1870.	1.2	29
838	Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. <i>Clinical Rheumatology</i> , 2017, 36, 2743-2750.	1.0	32
839	Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. <i>Rheumatology International</i> , 2017, 37, 2049-2058.	1.5	13
840	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients. <i>Scientific Reports</i> , 2017, 7, 12023.	1.6	17
841	Impact of Genetic Variants of ATP Binding Cassette B1, AICAR Transformylase/IMP Cyclohydrolase, Folyl-polyglutamate Synthetase, and Methylenetetrahydrofolate Reductase on Methotrexate Toxicity. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 318-325.	0.2	1
842	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
843	Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. <i>Rheumatology International</i> , 2017, 37, 2079-2085.	1.5	56
844	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	1.6	41
845	Development of a Canadian Core Clinical Dataset to Support High-quality Care for Canadian Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1813-1822.	1.0	11
846	The role of nurse practitioners in delivering rheumatology care and services. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 673-681.	0.5	13
847	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	0.9	49
848	Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. <i>Rheumatology</i> , 2017, 56, iv49-iv62.	0.9	37

#	ARTICLE	IF	CITATIONS
849	Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. <i>RMD Open</i> , 2017, 3, e000453.	1.8	2
851	Treatment with Biologicals in Rheumatoid Arthritis: An Overview. <i>Rheumatology and Therapy</i> , 2017, 4, 247-261.	1.1	115
852	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 2093-2101.	0.9	59
853	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 309-332.	1.1	20
854	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 375-389.	1.1	12
855	Anti-Rheumatic Therapy and Comorbidity. , 2017, , 345-380.		0
856	Impact of Comorbidity. , 2017, , 33-52.		0
858	Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. <i>Rheumatology International</i> , 2017, 37, 1789-1798.	1.5	20
859	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. <i>The Cochrane Library</i> , 2017, 2017, CD007649.	1.5	40
860	Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative. <i>Clinical Rheumatology</i> , 2017, 36, 2421-2430.	1.0	11
861	Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?. <i>RMD Open</i> , 2017, 3, e000492.	1.8	15
863	Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis. <i>Scientific Reports</i> , 2017, 7, 11353.	1.6	13
864	Prognostic Factors for Permanent Work Disability in Patients With Rheumatoid Arthritis Who Received Combination Therapy of Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 376-382.	0.5	5
865	Discussion of Methotrexate Dosage. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrhumdis-2017-212358.	0.5	1
866	Safety, Tolerability, and Pharmacodynamics of <sc>ABT</sc>â€122, a Tumor Necrosis Factorâ€ and Interleukinâ€17â€ Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2283-2291.	2.9	27
867	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2054-2060.	0.5	21
868	Editorial: Is Rheumatoid Arthritis a Mortal Disease?. <i>Arthritis and Rheumatology</i> , 2017, 69, 1509-1511.	2.9	1
869	A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 672-678.	0.7	52

#	ARTICLE	IF	CITATIONS
870	Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. <i>Clinical Therapeutics</i> , 2017, 39, 1600-1617.	1.1	27
871	Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
872	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1166-1184.	0.9	12
873	Terapia biológica en la artritis reumatoide temprana: eficacia en la remisión de la enfermedad. <i>Revista Colombiana De Reumatología</i> , 2017, 24, 164-176.	0.0	1
874	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. <i>Rheumatology</i> , 2017, 56, 1746-1754.	0.9	49
875	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 364-369.	1.0	21
876	Precision Medicine in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 377-387.	0.8	42
877	Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes. <i>Inflammation Research</i> , 2017, 66, 999-1009.	1.6	10
878	Beyond disease activity to overall disease severity in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 624-626.	3.7	5
879	Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. <i>Clinical Rheumatology</i> , 2017, 36, 1989-1996.	1.0	10
880	Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions. <i>Medicine (United States)</i> , 2017, 96, e6021.	0.4	20
881	Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF- α inhibitor. <i>Medicine (United States)</i> , 2017, 96, e6055.	0.4	12
882	The Reliability of Disease Activity Score in 28 Joints—C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 102-106.	0.5	27
883	A Quality Improvement Approach to Rheumatoid Arthritis Management With Biologic Disease-Modifying Antirheumatic Drugs. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 66-69.	0.5	1
884	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	1.0	21
885	Correlation between hand bone mineral density and joint destruction in established rheumatoid arthritis. <i>Journal of Orthopaedics</i> , 2017, 14, 461-465.	0.6	7
886	Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 671-682.	0.6	4
887	Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1345580.	0.8	33

#	ARTICLE	IF	CITATIONS
888	Preference for shared decision-making in Japanese patients with rheumatoid arthritis. <i>Cogent Medicine</i> , 2017, 4, 1353262.	0.7	8
889	The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 43-50.	0.7	7
890	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. <i>Clinical Rheumatology</i> , 2017, 36, 2187-2192.	1.0	6
891	Tuberculosis and biologics in rheumatology: A special situation. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1313-1325.	0.9	22
892	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1795-1797.	0.9	1
893	Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. <i>Advances in Therapy</i> , 2017, 34, 2316-2332.	1.3	10
894	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. <i>Nature Reviews Rheumatology</i> , 2017, 13, 707-718.	3.5	139
895	Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. <i>BioDrugs</i> , 2017, 31, 533-544.	2.2	45
896	Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries. <i>Clinical Rheumatology</i> , 2017, 36, 2789-2797.	1.0	14
897	Clinical Outcome and Long-term Remission in JIA. <i>Current Rheumatology Reports</i> , 2017, 19, 75.	2.1	26
898	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017, 56, 1586-1596.	0.9	20
899	Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study. <i>Clinical Rheumatology</i> , 2017, 36, 517-525.	1.0	6
900	Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1129-1143.	1.4	86
901	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. <i>Rheumatology</i> , 2017, 56, 1721-1728.	0.9	4
902	Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain. <i>Inflammation Research</i> , 2017, 66, 855-862.	1.6	9
903	Experimental study on the effect of different moxibustion durations on rats with rheumatoid arthritis. <i>Journal of Acupuncture and Tuina Science</i> , 2017, 15, 177-183.	0.1	3
904	Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 7.	0.8	12
905	Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 51.	1.5	21

#	ARTICLE	IF	CITATIONS
906	It's so hard taking pills when you don't know what they're for: a qualitative study of patients' medicine taking behaviours and conceptualisation of medicines in the context of rheumatoid arthritis. <i>BMC Health Services Research</i> , 2017, 17, 303.	0.9	13
907	Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 110.	1.0	23
908	Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. <i>Arthritis Research and Therapy</i> , 2017, 19, 92.	1.6	17
909	Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. <i>Clinical Rheumatology</i> , 2017, 36, 1699-1706.	1.0	12
910	Ultrasound and follow-up of rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 531-536.	0.8	22
911	Incidence and risk factors for cervical lesions in patients with rheumatoid arthritis under the current pharmacologic treatment paradigm. <i>Modern Rheumatology</i> , 2017, 27, 593-597.	0.9	18
912	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). <i>Clinical Rheumatology</i> , 2017, 36, 59-66.	1.0	13
913	Healthcare utilization for arthritis by indigenous populations of Australia, Canada, New Zealand, and the United States: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 665-674.	1.6	30
914	A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. <i>Postgraduate Medicine</i> , 2017, 129, 118-125.	0.9	14
915	Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2017, 69, 277-290.	2.9	146
916	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , 2017, 69, 518-528.	2.9	23
917	Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. <i>Current Medical Research and Opinion</i> , 2017, 33, 101-107.	0.9	24
918	Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2017, 27, 252-256.	0.9	12
919	Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1185-1192.	0.9	12
920	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 313-322.	1.5	32
921	Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. <i>Modern Rheumatology</i> , 2017, 27, 246-251.	0.9	4
922	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017, 69, 783-793.	1.5	32
923	Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis. , 2017, , .		3

#	ARTICLE	IF	CITATIONS
924	Validation of FLAREâ€”RA, a Selfâ€”Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare. <i>Arthritis and Rheumatology</i> , 2017, 69, 309-319.	2.9	34
925	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	1.6	19
926	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. <i>Clinical Rheumatology</i> , 2017, 36, 15-24.	1.0	22
927	Prevalence of schizophrenia in patients with psoriasis: a nationwide study. <i>Dermatologica Sinica</i> , 2017, 35, 1-6.	0.2	36
928	Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. <i>Patient Education and Counseling</i> , 2017, 100, 126-132.	1.0	4
929	The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. <i>Clinical Rheumatology</i> , 2017, 36, 35-43.	1.0	30
930	Brief Michigan Hand Outcomes Questionnaire in rheumatoid arthritis: A cross-sectional study of 100 patients. <i>Hand Surgery and Rehabilitation</i> , 2017, 36, 24-29.	0.2	5
932	Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis. <i>Rheumatology</i> , 2017, 56, 223-230.	0.9	16
933	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Diseaseâ€”Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	2.9	310
935	Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. <i>Experimental Biology and Medicine</i> , 2017, 242, 355-373.	1.1	72
936	Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US. <i>Arthritis Care and Research</i> , 2017, 69, 794-800.	1.5	31
937	Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system. <i>Current Medical Research and Opinion</i> , 2017, 33, 605-611.	0.9	4
938	The therapeutic potential of plant flavonoids on rheumatoid arthritis. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3601-3613.	5.4	62
939	Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States. <i>Arthritis Care and Research</i> , 2017, 69, 21-27.	1.5	61
940	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Antiâ€”Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017, 58, 151-155.	2.8	32
941	cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. <i>Immunologic Research</i> , 2017, 65, 307-325.	1.3	10
942	Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 459-468.	1.0	59
943	EULAR recommendations for the management of rheumatoid arthritis: what is new in 2017 and its applicability in our local setting. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017, 17, 47-52.	0.1	1

#	ARTICLE	IF	CITATIONS
944	Biological therapy in early rheumatoid arthritis: Efficacy in disease remission. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2017, 24, 164-176.	0.1	0
946	SP0090â€¦Comorbidity-adapted exercise for patients with knee osteoarthritis. , 2017, , .		0
947	Comparison of the Disease Activity Score-28 Based on the Erythrocyte Sedimentation Rate and C-reactive Protein in Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2017, 24, 287.	0.4	7
948	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. <i>Frontiers in Pharmacology</i> , 2017, 8, 322.	1.6	21
949	Tamarixinin A Alleviates Joint Destruction of Rheumatoid Arthritis by Blockade of MAPK and NF-Î²B Activation. <i>Frontiers in Pharmacology</i> , 2017, 8, 538.	1.6	19
950	Managing the drug treatment of rheumatoid arthritis. <i>Australian Prescriber</i> , 2017, 40, 51-58.	0.5	57
951	Traditional DMARDs. , 2017, , 958-982.e7.		3
952	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1969-1978.	2.0	11
953	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 211-223.	2.0	17
954	Immunosuppressive Drugs. , 2017, , 983-998.e4.		5
955	Isoegomaketone Alleviates the Development of Collagen Antibody-Induced Arthritis in Male Balb/c Mice. <i>Molecules</i> , 2017, 22, 1209.	1.7	10
956	Phytomedicine in Joint Disorders. <i>Nutrients</i> , 2017, 9, 70.	1.7	80
958	BehÃ§etâ€™s Disease. , 2017, , 505-526.		0
959	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. <i>Reumatismo</i> , 2017, 69, 30.	0.4	36
960	Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis. <i>Frontiers in Immunology</i> , 2017, 8, 1191.	2.2	24
961	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-15.	0.9	24
962	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-8.	0.9	6
963	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	93

#	ARTICLE	IF	CITATIONS
964	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1593-1603.	2.0	85
965	<i>Pharmacology in Orthopedic Physical Therapy</i> . , 2017, , 112-124.		0
966	<i>Cancer Risk in Rheumatic Diseases</i> . , 2017, , 547-559.		0
967	Etanercept (Enbrel<sup>®®</sup>) alternative storage at ambient temperature. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 87-99.	0.8	6
968	Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1253-1264.	0.8	5
969	Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 67-79.	0.8	77
970	Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. <i>PLoS ONE</i> , 2017, 12, e0179179.	1.1	37
971	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. <i>PLoS ONE</i> , 2017, 12, e0183294.	1.1	30
972	Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 332.	0.8	19
973	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 591.	0.7	14
974	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. <i>Arthritis Research and Therapy</i> , 2017, 19, 170.	1.6	16
975	A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. <i>Arthritis Research and Therapy</i> , 2017, 19, 185.	1.6	11
976	IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 182.	1.6	35
977	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 193.	1.6	14
978	Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning. <i>Arthritis Research and Therapy</i> , 2017, 19, 220.	1.6	4
979	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 258.	1.6	3
980	Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6735-6746.	3.3	79
981	Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 95-106.	0.8	15

#	ARTICLE	IF	CITATIONS
982	Age-related trends in injection site reaction incidence induced by the tumor necrosis factor- $\hat{\pm}$ (TNF- $\hat{\pm}$) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. <i>International Journal of Medical Sciences</i> , 2017, 14, 102-109.	1.1	21
983	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. <i>Reumatologia</i> , 2017, 55, 284-289.	0.5	6
984	Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1133-1142.	0.8	14
985	Treatment of Rheumatoid Arthritis. , 2017, , 1187-1212.e5.		0
986	Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospektivo Condotta in un Centro Ospedaliero del Centro Italia. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000271.	0.2	0
987	Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. <i>Oncotarget</i> , 2017, 8, 48375-48384.	0.8	11
988	Pharmacologic treatment of rheumatoid arthritis. <i>Journal of the Korean Medical Association</i> , 2017, 60, 156.	0.1	4
989	A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee. <i>Modern Rheumatology</i> , 2018, 28, 550-554.	0.9	4
990	Secukinumab after anti-tumour necrosis factor- $\hat{\pm}$ therapy: a phase III study in active rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 276-281.	0.6	30
992	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2018, , 121-161.	0.1	4
994	Adherence to recommendations for the use of anti- $\hat{\pm}$ tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 880-890.	0.9	8
995	Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan. <i>Rheumatology and Therapy</i> , 2018, 5, 135-148.	1.1	8
997	Immunogenicity of biologic therapies: causes and consequences. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 513-523.	1.3	51
998	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 43-55.	1.1	4
999	Quality of life in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 405-417.	1.3	127
1000	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
1002	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428.	2.9	21
1003	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018, 37, 1417-1420.	1.0	1

#	ARTICLE	IF	CITATIONS
1004	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212934.	0.5	19
1005	Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly. <i>Drugs and Aging</i> , 2018, 35, 379-387.	1.3	7
1006	Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. <i>Clinical Rheumatology</i> , 2018, 37, 1189-1197.	1.0	44
1007	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	0.9	47
1008	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	55
1009	Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 259-269.	0.6	10
1010	Person-centred care in nurse-led outpatient rheumatology clinics: Conceptualization and initial development of a measurement instrument. <i>Musculoskeletal Care</i> , 2018, 16, 287-295.	0.6	8
1011	Experience and Context Shape Patient and Clinician Goals For Treatment of Rheumatoid Arthritis: A Qualitative Study. <i>Arthritis Care and Research</i> , 2018, 70, 1614-1620.	1.5	16
1012	Sleep disorders associated with risk of rheumatoid arthritis. <i>Sleep and Breathing</i> , 2018, 22, 1083-1091.	0.9	9
1013	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). <i>Rheumatology</i> , 2018, 57, 337-344.	0.9	92
1014	Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2018, 40, 156-165.e5.	1.1	31
1015	Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. <i>Modern Rheumatology</i> , 2018, 28, 780-788.	0.9	14
1016	Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 901-908.	1.0	11
1018	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
1019	Trying to find an answer for an old question: does Rituximab increase the risk of serious infections in patients with rheumatoid arthritis?. <i>Rheumatology</i> , 2018, 57, 1505-1506.	0.9	0
1020	Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. <i>BMC Rheumatology</i> , 2018, 2, 1.	0.6	15
1021	Controlled Joint Inflammation but Still No Remission? It's Time to Attend to Depressive Symptoms. <i>Journal of Rheumatology</i> , 2018, 45, 585-587.	1.0	3
1022	Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 142-149.	0.2	3

#	ARTICLE	IF	CITATIONS
1023	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. <i>Bone Research</i> , 2018, 6, 15.	5.4	947
1024	Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients. <i>Internal Medicine</i> , 2018, 57, 663-670.	0.3	30
1025	Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1776-1788.	1.1	37
1026	Biologic agents in inflammatory arthritis. <i>British Journal of General Practice</i> , 2018, 68, 204-205.	0.7	4
1027	Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial. <i>Rheumatology and Therapy</i> , 2018, 5, 123-134.	1.1	8
1028	Systems approach for classifying the response to biological therapies in patients with rheumatoid arthritis in clinical practice. <i>European Journal of Integrative Medicine</i> , 2018, 19, 65-71.	0.8	1
1029	Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. <i>Joint Bone Spine</i> , 2018, 85, 679-685.	0.8	7
1030	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 351-359.	0.6	11
1031	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	1.8	20
1032	Treat to Target in Juvenile Idiopathic Arthritis: Challenges and Opportunities. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 29-43.	0.6	3
1033	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212426.	0.5	23
1035	Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 170-178.	0.9	18
1036	Recomendaciones sobre el uso de metrotexato parenteral en enfermedades reumáticas. <i>Reumatología Clínica</i> , 2018, 14, 142-149.	0.2	12
1037	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 164-174.	0.9	70
1038	Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients. <i>Modern Rheumatology</i> , 2018, 28, 30-38.	0.9	6
1039	Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty. <i>Clinical Rheumatology</i> , 2018, 37, 339-343.	1.0	6
1040	Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 66-75.	0.9	26
1041	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	1.5	84

#	ARTICLE	IF	CITATIONS
1042	Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2018, 85, 317-322.	0.8	29
1043	Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. <i>Modern Rheumatology</i> , 2018, 28, 227-234.	0.9	19
1044	Pharmacokinetics of ABT-122, a TNF- α - and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2018, 57, 613-623.	1.6	17
1045	Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1678-1685.	0.9	3
1046	Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. <i>Arthritis Care and Research</i> , 2018, 70, 525-532.	1.5	40
1047	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <sc>LORHEN</sc> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430.	0.9	22
1048	A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 56-65.	2.4	14
1049	Efficacité de la triple association de méthotrexate, sulfasalazine et hydroxychloroquine dans le traitement précoce de la polyarthrite rhumatoïde lorsque la réponse au méthotrexate est insuffisante: méta-analyse d'essais comparatifs randomisés. <i>Revue Du Rhumatisme (Edition Française)</i> , 2018, 85, 12-18.	0.0	0
1050	Methods for segmentation of rheumatoid arthritis bone erosions in high-resolution peripheral quantitative computed tomography (HR-pQCT). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 611-618.	1.6	32
1051	Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients: an intervention study. <i>Clinical Rheumatology</i> , 2018, 37, 331-337.	1.0	11
1052	Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 178-184.	0.6	4
1053	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. <i>Arthritis Care and Research</i> , 2018, 70, 834-841.	1.5	5
1054	Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase <sc>III</sc> Trial. <i>Arthritis Care and Research</i> , 2018, 70, 861-868.	1.5	17
1055	Phase <sc>III</sc> Randomized Study of <sc>SB</sc>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 40-48.	2.9	104
1056	Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 199-204.	1.0	6
1057	Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. <i>Heart</i> , 2018, 104, 119-126.	1.2	63
1058	Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 485-491.	1.6	14
1059	Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 801-806.	1.5	26

#	ARTICLE	IF	CITATIONS
1060	Tacrolimus regulates endoplasmic reticulum stress-mediated osteoclastogenesis and inflammation: In vitro and collagen-induced arthritis mouse model. <i>Cell Biology International</i> , 2018, 42, 393-402.	1.4	16
1061	Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e35-e35.	0.5	2
1062	Relationship between achievement of physical activity goal and characteristics of patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 606-610.	0.9	7
1063	Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 566-571.	0.8	9
1064	Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database. <i>Modern Rheumatology</i> , 2018, 28, 435-443.	0.9	7
1065	Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 877-883.	1.5	51
1066	Perception des poussées de polyarthrite rhumatoïde de telles que rapportées par les patients: sous-analyse de l'essai STRASS sur les stratégies de diminution progressive du traitement. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 353-358.	0.0	0
1067	Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 630-638.	1.6	15
1068	Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. <i>Joint Bone Spine</i> , 2018, 85, 561-567.	0.8	65
1069	Defining and characterizing sustained remission in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 885-893.	1.0	6
1070	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , 2018, 28, 770-779.	0.9	5
1071	Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 362-372.	0.9	8
1072	Preventing progression from arthralgia to arthritis: targeting the right patients. <i>Nature Reviews Rheumatology</i> , 2018, 14, 32-41.	3.5	91
1073	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018, 45, 177-187.	1.0	18
1074	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.5	22
1075	Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. <i>Rheumatology International</i> , 2018, 38, 579-587.	1.5	13
1076	The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 757-764.	1.6	38
1077	Risk of tuberculosis comparison in new users of antitumour necrosis factor and with existing disease-modifying antirheumatic drug therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 256-264.	0.7	11

#	ARTICLE	IF	CITATIONS
1078	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	0.9	36
1079	Vagal influences in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 1-11.	0.6	17
1080	Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study. <i>Modern Rheumatology</i> , 2018, 28, 221-226.	0.9	5
1081	Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective. <i>Modern Rheumatology</i> , 2018, 28, 1-8.	0.9	66
1082	Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes. <i>Modern Rheumatology</i> , 2018, 28, 506-512.	0.9	3
1083	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
1084	Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 501-506.	1.6	13
1085	Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2018, 5, 160-164.	1.3	10
1086	Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e12658.	0.4	37
1087	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. <i>Chinese Medical Journal</i> , 2018, 131, 2683-2692.	0.9	28
1088	FRI0560 Quantitative ct indexes in the evaluation of interstitial lung disease related to rheumatoid arthritis. , 2018, , .		0
1089	Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .	1.2	2
1090	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 733-747.	0.8	18
1091	Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 103-111.	0.8	11
1092	Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China. <i>BMJ Open</i> , 2018, 8, e023798.	0.8	0
1093	MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 47.	0.3	2
1094	An audit of the use of hydroxychloroquine in rheumatology clinics. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky013.	0.3	3
1095	Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. <i>Archives of Rheumatology</i> , 2018, 33, 251-272.	0.3	3

#	ARTICLE	IF	CITATIONS
1096	Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. <i>Immunological Medicine</i> , 2018, 41, 181-186.	1.4	6
1097	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018, 4, e000813.	1.8	11
1098	Serum adiponectin as a predictor of laboratory response to anti-TNF- α therapy in rheumatoid arthritis. <i>Central-European Journal of Immunology</i> , 2018, 43, 289-294.	0.4	3
1099	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Various Biologic DMARDs. <i>Frontiers in Pharmacology</i> , 2018, 9, 1303.	1.6	7
1100	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , 2018, 57, vii23-vii31.	0.9	9
1101	Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014. <i>Archives of Medical Science</i> , 2018, 14, 569-571.	0.4	7
1102	Emergent Complications of Rheumatoid Arthritis. <i>Journal of Emergency Medicine</i> , 2018, 55, 647-658.	0.3	11
1103	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	0.9	24
1104	Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii32-vii41.	0.9	1
1105	Psychometric validation of an empowerment scale for Spanish-speaking patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 244.	1.6	3
1106	Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1943-1950.	0.9	3
1107	Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide Korean College of Rheumatology BIOlogics (KOBIO) registry. <i>PLoS ONE</i> , 2018, 13, e0205651.	1.1	13
1108	Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.	0.8	5
1109	Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. <i>Rheumatology and Therapy</i> , 2018, 5, 551-565.	1.1	9
1110	Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis. <i>Inflammopharmacology</i> , 2018, 26, 1375-1381.	1.9	9
1111	Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 502-516.	2.6	338
1112	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 572-582.	0.4	19
1113	A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 375-397.	0.8	7

#	ARTICLE	IF	CITATIONS
1114	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 349-358.	0.8	19
1115	UK–South Asian patients’ experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 489-497.	0.8	8
1116	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS ONE, 2018, 13, e0203084.	1.1	43
1117	Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1100-1105.	1.1	27
1118	Concomitant use of lowâledose methotrexate and <scp>NSAIDs</scp> and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiology and Drug Safety, 2018, 27, 885-893.	0.9	44
1119	Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatology Advances in Practice, 2018, 2, rky005.	0.3	33
1120	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatology and Therapy, 2018, 5, 341-353.	1.1	9
1121	Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology, 2018, 57, 1453-1460.	0.9	53
1122	Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: Results from a crossâlesectional study. Journal of Periodontology, 2018, 89, 1310-1317.	1.7	34
1123	Hyaluronic acid-conjugated pH-sensitive liposomes for targeted delivery of prednisolone on rheumatoid arthritis therapy. Nanomedicine, 2018, 13, 1037-1049.	1.7	40
1124	Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Internal Medicine Journal, 2018, 48, 1185-1192.	0.5	0
1125	Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania. BioMed Research International, 2018, 2018, 1-8.	0.9	14
1126	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. Rheumatology International, 2018, 38, 1911-1918.	1.5	23
1127	Biosimilars Have Arrived: Rituximab. Arthritis, 2018, 2018, 1-6.	2.0	30
1128	Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?. BioMed Research International, 2018, 2018, 1-9.	0.9	33
1129	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatology and Therapy, 2018, 5, 383-401.	1.1	11
1130	Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. Journal of Rheumatology, 2018, 45, 1353-1360.	1.0	7
1131	Rheumatologic Rehabilitation. , 2018, , 208-213.e3.		1

#	ARTICLE	IF	CITATIONS
1132	Anti-rheumatic medication and salivary MMP-8, a biomarker for periodontal disease. <i>Oral Diseases</i> , 2018, 24, 1562-1571.	1.5	17
1133	Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 539-547.	1.3	8
1134	Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 39-47.	2.0	46
1135	Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. <i>Rheumatology</i> , 2018, 57, 1830-1837.	0.9	51
1136	Combination of NF- κ B targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis. <i>Journal of Nanobiotechnology</i> , 2018, 16, 58.	4.2	74
1137	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	1.6	22
1138	Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease. <i>Inflammopharmacology</i> , 2018, 26, 1183-1188.	1.9	14
1139	Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models. <i>Frontiers in Pharmacology</i> , 2018, 9, 20.	1.6	31
1140	Stevens-Johnson syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature. <i>Biomedical Reports</i> , 2018, 9, 37-41.	0.9	8
1141	Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1151-1166.	0.8	41
1142	Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 1825-1831.	1.5	1
1143	Vaccinations in Rheumatology. , 2018, , 411-426.		0
1144	Synovial tissue quantitative proteomics analysis reveals paeoniflorin decreases LIFR and ASPN proteins in experimental rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 463-473.	2.0	13
1145	The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 105.	1.6	13
1146	Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 1662.	2.2	39
1147	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 621.	2.2	21
1148	Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. <i>Frontiers in Immunology</i> , 2018, 9, 950.	2.2	29
1149	Rheumatoid Arthritis: A Novel Approach in Diagnosis and Treatment. <i>Serbian Journal of Experimental and Clinical Research</i> , 2018, ,	0.2	0

#	ARTICLE	IF	CITATIONS
1150	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1010-1017.	0.5	14
1151	Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1513-1521.	0.8	3
1152	Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. <i>Arthritis Research and Therapy</i> , 2018, 20, 39.	1.6	26
1153	Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. <i>Journal of Translational Medicine</i> , 2018, 16, 18.	1.8	33
1154	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	1.6	29
1155	Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?. <i>Arthritis Research and Therapy</i> , 2018, 20, 15.	1.6	8
1156	Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. <i>Arthritis Research and Therapy</i> , 2018, 20, 81.	1.6	8
1157	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , 2018, 38, 4.	1.5	32
1158	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. <i>Arthritis and Rheumatology</i> , 2018, 70, 1557-1564.	2.9	17
1159	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adoption of the 2015 American College of Rheumatology guidelines. <i>Clinical Rheumatology</i> , 2018, 37, 2947-2959.	1.0	13
1160	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
1161	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 1533-1540.	0.9	20
1162	Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. <i>Journal of Translational Medicine</i> , 2018, 16, 156.	1.8	6
1163	Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. <i>Translational Research</i> , 2018, 199, 24-38.	2.2	13
1164	Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212612.	0.5	19
1165	The combination of FK506 and an anti-CD147 mAb exerts potential therapeutic effects on a mouse model of collagen-induced arthritis. <i>Molecular Immunology</i> , 2018, 101, 1-9.	1.0	10
1166	The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials. <i>Bone</i> , 2018, 114, 172-180.	1.4	43
1167	Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. <i>PLoS ONE</i> , 2018, 13, e0195550.	1.1	48

#	ARTICLE	IF	CITATIONS
1168	The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. <i>Modern Rheumatology</i> , 2019, 29, 581-588.	0.9	17
1169	Cystathionine- β -lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis. <i>Cellular and Molecular Immunology</i> , 2019, 16, 694-705.	4.8	47
1170	The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 310-317.	1.5	35
1171	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 115-126.	0.5	11
1172	The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. <i>Rheumatology</i> , 2019, 58, 580-587.	0.9	20
1173	1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF- κ B signaling pathway. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 430-440.	1.3	6
1174	Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 821-827.	1.6	18
1175	Effectiveness and safety of initiating adalimumab plus 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. <i>Modern Rheumatology</i> , 2019, 29, 572-580.	0.9	7
1176	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. <i>Rheumatology and Therapy</i> , 2019, 6, 461-471.	1.1	52
1177	High prevalence of abnormalities on chest radiography in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 3375-3380.	1.0	3
1178	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). <i>Archives of Dermatological Research</i> , 2019, 311, 753-760.	1.1	11
1179	The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treatment. <i>Cells</i> , 2019, 8, 871.	1.8	18
1180	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	1.1	12
1181	Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study. <i>Rheumatology International</i> , 2019, 39, 2015-2024.	1.5	2
1182	Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2019, 35, 2025-2033.	0.9	2
1183	Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. <i>Clinical Rheumatology</i> , 2019, 38, 3049-3059.	1.0	3
1184	Intracranial Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis. <i>World Neurosurgery</i> , 2019, 130, 138-141.	0.7	10
1185	Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. <i>Clinical Rheumatology</i> , 2019, 38, 3217-3225.	1.0	15

#	ARTICLE	IF	CITATIONS
1186	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. JAMA - Journal of the American Medical Association, 2019, 322, 315.	3.8	210
1187	Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania. BioMed Research International, 2019, 2019, 1-7.	0.9	3
1188	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	8
1189	Rheumatoid Arthritis and Gastrointestinal Tract Lesions (NSAID Ulcers, Amyloidosis). , 2019, , 97-121.		2
1190	Therapeutic impact of statins on the lipid profile and cardiovascular risk of patients with rheumatoid arthritis: Systematic literature review and meta-analysis. Revista Colombiana De ReumatologÃa (English Edition), 2019, 26, 40-47.	0.1	0
1191	Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. Journal of Clinical Medicine, 2019, 8, 938.	1.0	127
1192	Optimising low-dose methotrexate for rheumatoid arthritisâ€”A review. British Journal of Clinical Pharmacology, 2019, 85, 2228-2234.	1.1	36
1193	Risque des erreurs mÃ©dicamenteuses liÃ©es au mÃ©thotrexate Ã faible doseÃ: donnÃ©es des centres antipoison et de pharmacovigilance franÃ§ais. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 471-475.	0.0	0
1194	Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis. Pharmacogenomics, 2019, 20, 1235-1245.	0.6	25
1195	Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 2009-2016.	0.9	2
1196	Traditional Chinese Medicine as a Treatment for Rheumatoid Arthritis: From Empirical Practice to Evidence-Based Therapy. Engineering, 2019, 5, 895-906.	3.2	32
1197	The use of leukocytesâ€™ secretome to individually target biological therapy in autoimmune arthritis: a case report. Clinical and Translational Medicine, 2019, 8, 19.	1.7	5
1198	Top 100 cited articles on rheumatoid arthritis. Medicine (United States), 2019, 98, e14523.	0.4	35
1199	Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research, 2019, 7, 27.	5.4	19
1200	Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clinical Rheumatology, 2019, 38, 2967-2976.	1.0	37
1201	<p>Quality of life in Ecuadorian patients with established rheumatoid arthritis</p>. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 199-205.	0.8	5
1202	Subclinical synovitis measured by ultrasound in rheumatoid arthritis patients with clinical remission induced by synthetic and biological modifying disease drugs. ReumatologÃa ClÃnica (English Edition), 2019, 15, 218-222.	0.2	0
1203	Nouveaux concepts destinÃ©s Ã rÃ©duire la toxicitÃ© des glucocorticoÃ©s. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0,784314	0.0	0

#	ARTICLE	IF	CITATIONS
1204	Treat-to-target in rheumatoid arthritis “ are we there yet?. Nature Reviews Rheumatology, 2019, 15, 180-186.	3.5	86
1205	<p>Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis</p>. Patient Preference and Adherence, 2019, Volume 13, 157-163.	0.8	4
1206	Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain. Journal of Clinical Rheumatology, 2019, 25, 258-263.	0.5	8
1207	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. Journal of Rheumatology, 2019, 46, 555-563.	1.0	17
1208	The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets. Current Drug Targets, 2019, 20, 970-981.	1.0	29
1209	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2019, 28, 573-581.	1.9	33
1210	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. BMC Rheumatology, 2019, 3, 3.	0.6	4
1211	The “totality-of-the-evidence” approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985253.	1.4	11
1212	“Living a normal life” a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis. BMC Rheumatology, 2019, 3, 2.	0.6	13
1213	A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Research and Therapy, 2019, 21, 153.	1.6	71
1214	<p>Abatacept: from a budget impact model to cost-effectiveness analysis “ data from RCT and real life</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 405-409.	0.7	1
1215	The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. Journal of Clinical Medicine, 2019, 8, 826.	1.0	11
1216	Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatology International, 2019, 39, 1331-1341.	1.5	17
1217	Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. ReumatologĀa ClĀnica (English Edition), 2019, 15, 133-139.	0.2	2
1218	Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-. PLoS ONE, 2019, 14, e0216624.	1.1	46
1219	Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis. International Journal of Rheumatic Diseases, 2019, 22, 1361-1370.	0.9	22
1220	Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. Arthritis Research and Therapy, 2019, 21, 115.	1.6	7
1221	Fighting rheumatoid arthritis: Kv1.3 as a therapeutic target. Biochemical Pharmacology, 2019, 165, 214-220.	2.0	18

#	ARTICLE	IF	CITATIONS
1223	Antigen-induced arthritis of the temporomandibular joint via repeated injections of bovine serum albumin in domestic pigs. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2019, 47, 932-939.	0.7	5
1225	Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2019, 2, e190606.	2.8	135
1226	Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1565889.	0.8	7
1227	In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 72.	1.6	39
1228	Experience of Biological Therapy Units in Rheumatoid Arthritis and Other Autoimmune Diseases. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 61-62.	0.2	0
1230	Medication Adherence and Coping Strategies in Patients with Rheumatoid Arthritis: A Cross-Sectional Study. <i>International Journal of Rheumatology</i> , 2019, 2019, 1-8.	0.9	17
1231	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	2.5	64
1232	Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-time Anonymous Liaison system: The RA T2T PORTAL study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 874-879.	0.9	12
1233	Impacto terapéutico de las estatinas en el perfil lipídico y riesgo cardiovascular en pacientes con artritis reumatoide: Revisión sistemática de la literatura y metanálisis. <i>Revista Colombiana De Reumatología</i> , 2019, 26, 40-47.	0.0	1
1234	Experiencia de unidades de terapias biológicas en artritis reumatoide y otras enfermedades autoinmunes. <i>Reumatología Clínica</i> , 2019, 15, 61-62.	0.2	2
1235	Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach. <i>International Journal for Equity in Health</i> , 2019, 18, 22.	1.5	9
1236	MR and ultrasound of the hands and wrists in rheumatoid arthritis. Part II. Added clinical value. <i>Skeletal Radiology</i> , 2019, 48, 837-857.	1.2	12
1237	Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients. <i>Reumatología Clínica (English)</i> Tj ETQq0 0 0.0gBT /Overlock 10 T	0.2	0
1238	Nichtarteriitische anteriore ischämische Optikusneuropathie bei Patienten mit rheumatoider Arthritis. <i>Spektrum Der Augenheilkunde</i> , 2019, 33, 6-13.	0.2	0
1239	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 1483-1493.	0.9	18
1240	Current advances in the treatment of giant cell arteritis: the role of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1982722.	1.2	9
1241	A systematic review of the factors associated with the initiation of biologics in patients with rheumatological conditions. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 163-169.	0.5	4
1242	Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study. <i>BMJ Open</i> , 2019, 9, e031467.	0.8	8

#	ARTICLE	IF	CITATIONS
1243	Health-care professionalsâ€™ perceptions of interacting with patients of South Asian origin attending early inflammatory arthritis clinics. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz042.	0.3	2
1244	Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent?. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 369-373.	0.4	10
1245	Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis: an umbrella review. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 1494-1531.	1.7	28
1246	<p>Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorovâ€“Smirnov Algorithm</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 369-375.	0.4	3
1247	Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2019, 21, 257.	1.6	19
1248	Total knee arthroplasty for treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2019, 98, e16558.	0.4	5
1249	Effectiveness of non-pharmacological and non-surgical interventions on the impact of rheumatoid arthritis. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 22-27.	1.7	4
1250	Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 264.	1.6	7
1251	Bone Marrow Mesenchymal Stem Cells Decrease the Expression of RANKL in Collagen-Induced Arthritis Rats via Reducing the Levels of IL-22. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	0.9	9
1252	Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes. <i>Frontiers in Immunology</i> , 2019, 10, 2992.	2.2	8
1253	The effects of methotrexate and hydroxychloroquine combination therapy<i>vs</i> methotrexate monotherapy in early rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 131-134.	0.9	14
1254	Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. <i>Rheumatology</i> , 2019, 58, 803-810.	0.9	21
1255	Study of the adoptive immunotherapy on rheumatoid arthritis with Thymus-derived invariant natural killer T cells. <i>International Immunopharmacology</i> , 2019, 67, 427-440.	1.7	14
1256	Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, annrheumdis-2018-214075.	0.5	28
1257	Association between cumulative methotrexate dose, nonâ€“invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 214-221.	0.9	28
1258	Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. <i>Rheumatology International</i> , 2019, 39, 131-140.	1.5	16
1259	Challenges in Implementing Treat-to-Target Strategies in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 101-112.	0.8	14
1260	FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 517-531.	1.0	33

#	ARTICLE	IF	CITATIONS
1261	EBV-antibody positive mucocutaneous ulcer arising in rheumatoid arthritis patients treated with methotrexate: Single center series of nine cases. <i>Pathology International</i> , 2019, 69, 21-28.	0.6	40
1262	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	1.8	41
1263	New concepts to reduce glucocorticoid toxicity. <i>Joint Bone Spine</i> , 2019, 86, 715-723.	0.8	7
1264	Methotrexate in Patients With Rheumatoid Arthritis in Spain: Subanalysis of the AR Excellence Project. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 338-342.	0.2	1
1265	CP-25 reverses prostaglandin E4 receptor desensitization-induced fibroblast-like synoviocyte dysfunction via the G protein-coupled receptor kinase 2 in autoimmune arthritis. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1029-1039.	2.8	32
1266	Potential value of serum progranulin as an activity biomarker in rheumatoid arthritis patients: Relation to musculoskeletal ultrasonographic evaluation. <i>Egyptian Rheumatologist</i> , 2019, 41, 93-97.	0.5	3
1267	Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. <i>Clinical Rheumatology</i> , 2019, 38, 437-445.	1.0	9
1268	Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. <i>Journal of Rheumatology</i> , 2019, 46, 460-466.	1.0	9
1269	Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 282-284.	0.5	15
1270	Adverse consequences of low-dose methotrexate medication errors: data from French poison control and pharmacovigilance centers. <i>Joint Bone Spine</i> , 2019, 86, 351-355.	0.8	16
1271	A statistical method to convert published response rates into marginal distributions with an example application in psoriasis. <i>Pharmaceutical Statistics</i> , 2019, 18, 4-21.	0.7	1
1272	The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. <i>Modern Rheumatology</i> , 2019, 29, 795-801.	0.9	12
1273	Patient Perspectives on Intravenous Biologics for Rheumatologic Disease. <i>Arthritis Care and Research</i> , 2019, 71, 1234-1242.	1.5	11
1274	MMP-8 and TIMP-1 are associated to periodontal inflammation in patients with rheumatoid arthritis under methotrexate immunosuppression – First results of a cross-sectional study. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 386-394.	1.5	20
1275	Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis. <i>American Journal of Therapeutics</i> , 2019, 26, e358-e363.	0.5	10
1276	Supervivencia a largo plazo de los fármacos biológicos anti-TNF subcutáneos administrados durante los años 2008-2012 en una cohorte de pacientes con artritis reumatoide. <i>Reumatología Clínica</i> , 2019, 15, 54-57.	0.2	1
1277	Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis – A three-year study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 141-150.	1.5	25
1278	Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. <i>Reumatología Clínica</i> , 2019, 15, 133-139.	0.2	41

#	ARTICLE	IF	CITATIONS
1279	Subclinical synovitis measured by ultrasound in rheumatoid arthritis patients with clinical remission induced by synthetic and biological modifying disease drugs. <i>ReumatologĀa ClĀnica</i> , 2019, 15, 218-222.	0.2	8
1280	Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. <i>Rheumatology</i> , 2019, 58, 227-236.	0.9	37
1281	Is remission achievable in most patients with rheumatoid arthritis? Results suggest not. <i>Rheumatology</i> , 2019, 58, 187-188.	0.9	4
1282	Metotrexato en pacientes con artritis reumatoide en EspaĀa: subanĀlisis del proyecto AR Excellence. <i>ReumatologĀa ClĀnica</i> , 2019, 15, 338-342.	0.2	4
1283	Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 31-40.	0.9	104
1284	Eficacia y seguridad de la terapia combinada con fĀrmacos modificadores de la enfermedad sintĀticos en la artritis reumatoide: revisiĀn sistemĀtica de la literatura. <i>ReumatologĀa ClĀnica</i> , 2020, 16, 324-332.	0.2	4
1285	Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study. <i>ReumatologĀa ClĀnica</i> , 2020, 16, 319-323.	0.2	4
1286	LongĀerm Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of FollowĀUp in the PopulationĀBased Nordic Juvenile Idiopathic Arthritis Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 507-516.	1.5	108
1287	Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives. <i>Arthritis Care and Research</i> , 2020, 72, 544-552.	1.5	16
1288	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 1104-1111.	1.5	10
1289	Age at the time of hip fracture in patients with rheumatoid arthritis is 4 years greater than it was 10 years before, but is still younger than that of the general population. <i>Modern Rheumatology</i> , 2020, 30, 64-69.	0.9	2
1290	Efficacy of iguratimod <i>vs.</i> salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 249-258.	0.9	8
1291	How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence. <i>Arthritis Care and Research</i> , 2020, 72, 489-497.	1.5	7
1292	Detection of rheumatoid arthritis from hand radiographs using a convolutional neural network. <i>Clinical Rheumatology</i> , 2020, 39, 969-974.	1.0	52
1293	Systematic Review of Recommendations on the Use of DiseaseĀModifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. <i>Arthritis Care and Research</i> , 2020, 72, 309-318.	1.5	20
1295	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	1.0	16
1296	Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. <i>Current Medical Research and Opinion</i> , 2020, 36, 337-342.	0.9	5
1297	Feasibility of patient-oriented ultrasound joint selection: Cross-sectional observational study on rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 975-981.	0.9	3

#	ARTICLE	IF	CITATIONS
1298	The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. <i>Rheumatology International</i> , 2020, 40, 217-225.	1.5	3
1299	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and 12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. <i>Modern Rheumatology</i> , 2020, 30, 424-433.	0.9	1
1300	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. <i>Arthritis Care and Research</i> , 2020, 72, 1410-1419.	1.5	19
1301	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164.	0.9	21
1302	Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries. <i>Journal of Rheumatology</i> , 2020, 47, 510-517.	1.0	7
1303	A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. <i>Pharmacoeconomics</i> , 2020, 38, 39-56.	1.7	6
1304	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020, 40, 101-113.	1.2	14
1305	Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea. <i>Current Medical Research and Opinion</i> , 2020, 36, 343-351.	0.9	5
1306	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. <i>Annals of Hepatology</i> , 2020, 19, 5-16.	0.6	13
1307	Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review. <i>Reumatologia Clínica (English Edition)</i> , 2020, 16, 324-332.	0.2	4
1308	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as "satisfactory". <i>Rheumatology</i> , 2020, 59, 1853-1861.	0.9	8
1309	Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 132-140.	0.5	4
1310	A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort. <i>Rheumatology</i> , 2020, 59, 1566-1573.	0.9	1
1311	Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 779-786.	1.0	7
1312	Severe Mononeuritis Multiplex due to Rheumatoid Vasculitis in Rheumatoid Arthritis in Sustained Clinical Remission for Decades. <i>Internal Medicine</i> , 2020, 59, 705-710.	0.3	4
1313	Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. <i>Clinical Rheumatology</i> , 2020, 39, 375-379.	1.0	22
1314	Investigating MTX-Loaded magnetic nanocomposite particles for treatment of rheumatoid arthritis. <i>Journal of Magnetism and Magnetic Materials</i> , 2020, 499, 166171.	1.0	9
1315	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12

#	ARTICLE	IF	CITATIONS
1316	Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. <i>Network and Systems Medicine</i> , 2020, 3, 91-104.	2.7	26
1317	TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT) Tj ETQq1 1 0.784314 rgBT /Overlo 0.7 24	0.7	24
1318	Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 16645.	1.6	4
1319	Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1617-1624.	1.0	9
1320	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106101.	1.1	83
1321	<p>Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 249-256.	0.8	5
1322	Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions. <i>Vaccines</i> , 2020, 8, 688.	2.1	8
1323	An Update on Imaging in Rheumatoid Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 370-381.	0.6	2
1324	Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs. <i>Frontiers in Pharmacology</i> , 2020, 11, 572260.	1.6	1
1325	Increased frequency of intermetatarsal and submetatarsal bursitis in early rheumatoid arthritis: a large case-controlled MRI study. <i>Arthritis Research and Therapy</i> , 2020, 22, 277.	1.6	13
1326	Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2020, 16, 319-323.	0.2	0
1327	Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19. <i>Chemical Physics Letters</i> , 2020, 757, 137869.	1.2	41
1328	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	6.3	78
1329	A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-11.	0.6	12
1330	Growing Need for Diagnostic Precision in Rheumatoid Arthritis: Proposal of MR Imaging Criteria for Early Diagnosis. , 2020, , .		0
1331	<p>Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 203-206.	0.8	4
1332	DMARDsâ€™ Gut Microbiota Feedback: Implications in the Response to Therapy. <i>Biomolecules</i> , 2020, 10, 1479.	1.8	16
1333	Methotrexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-NaĀve Rheumatoid Arthritis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6847.	1.8	7

#	ARTICLE	IF	CITATIONS
1334	Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094622.	1.2	7
1336	Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune-mediated inflammatory diseases: A longitudinal population-based analysis using claims data. <i>Health Science Reports</i> , 2020, 3, e216.	0.6	4
1337	Prognostic factors for the short-term mortality of patients with rheumatoid arthritis admitted to intensive care units. <i>BMC Rheumatology</i> , 2020, 4, 64.	0.6	4
1338	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
1339	Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS—evaluation of whole blood, plasma, and serum as sample matrices. <i>Arthritis Research and Therapy</i> , 2020, 22, 125.	1.6	31
1340	Synovial tissue transcriptomes of long-standing rheumatoid arthritis are dominated by activated macrophages that reflect microbial stimulation. <i>Scientific Reports</i> , 2020, 10, 7907.	1.6	24
1341	Differential Diagnosis of Inflammatory Arthropathies by Musculoskeletal Ultrasonography: A Systematic Literature Review. <i>Frontiers in Medicine</i> , 2020, 7, 141.	1.2	15
1342	Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1890.	1.0	17
1343	Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. <i>Arthritis Care and Research</i> , 2021, 73, 1461-1469.	1.5	8
1344	Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. <i>BMC Rheumatology</i> , 2020, 4, 5.	0.6	4
1345	Anti-rheumatoid arthritis effects of flavonoids from <i>Daphne genkwa</i> . <i>International Immunopharmacology</i> , 2020, 83, 106384.	1.7	42
1346	Mixed methods study of a new model of care for chronic disease: co-design and sustainable implementation of group consultations into clinical practice. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa003.	0.3	6
1347	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 41.	1.6	10
1348	Statins and autoimmunity: State-of-the-art. , 2020, 214, 107614.		29
1349	Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e20824.	0.4	11
1350	Impact of Chronic DMARD Therapy in Patients With Rheumatoid Arthritis Undergoing Surgery of the Craniovertebral Junction. <i>Spine</i> , 2020, 45, 930-936.	1.0	9
1351	Rheumatoid Arthritis as a Risk Factor for Coronary Artery Calcification and Obstructive Coronary Artery Disease in Patients with Chest Pain: A Registry Based Cross-Sectional Study. <i>Clinical Epidemiology</i> , 2020, Volume 12, 679-689.	1.5	7
1352	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 155-166.	3.5	952

#	ARTICLE	IF	CITATIONS
1353	Recent Advances in Nanotheranostics for Treat-to-Target of Rheumatoid Arthritis. <i>Advanced Healthcare Materials</i> , 2020, 9, e1901541.	3.9	39
1354	Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies. <i>Arthritis and Rheumatology</i> , 2020, 72, 1072-1081.	2.9	7
1355	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. <i>Clinical and Translational Science</i> , 2020, 13, 743-751.	1.5	5
1356	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacept phase 2b ADDRESS II study. <i>Rheumatology</i> , 2020, 59, 2930-2938.	0.9	33
1357	Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study. <i>Rheumatology International</i> , 2020, 40, 1045-1049.	1.5	3
1358	Views on glucocorticoid therapy in rheumatology: the age of convergence. <i>Nature Reviews Rheumatology</i> , 2020, 16, 239-246.	3.5	71
1359	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2020, 37, 1479-1495.	1.3	12
1360	Tumour necrosis factor alpha promotes secretion of 14-3-3 σ by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , 2020, 22, 24.	1.6	16
1361	The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. <i>Rheumatology</i> , 2020, 59, 2471-2480.	0.9	33
1362	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors" data from a large national quality register. <i>Arthritis Research and Therapy</i> , 2020, 22, 15.	1.6	19
1363	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
1364	New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , 2020, 7, 117.	1.2	22
1365	Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 163-177.	1.1	6
1366	Treat-to-target strategies aiming at additional ultrasound remission is associated with better control of disease activity and less flare in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 113-121.	1.0	8
1367	Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. <i>Clinical Rheumatology</i> , 2021, 40, 1211-1220.	1.0	45
1368	Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 90-104.	1.0	14
1369	Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. <i>Joint Bone Spine</i> , 2021, 88, 105060.	0.8	6
1370	Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China. <i>Clinical Rheumatology</i> , 2021, 40, 1789-1798.	1.0	7

#	ARTICLE	IF	CITATIONS
1371	Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients. <i>Joint Bone Spine</i> , 2021, 88, 105057.	0.8	4
1372	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 639-647.	1.4	12
1373	Ibuprofen-loaded calcium phosphate granules: A new bone substitute for local relieving symptoms of osteoarthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105679.	1.9	6
1374	Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 3302-3311.	0.7	1
1375	Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2333-2340.	1.1	4
1376	Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study. <i>Advances in Therapy</i> , 2021, 38, 366-385.	1.3	16
1377	Atopic dermatitis as a risk factor for severe visual field loss in youth—a retrospective cohort study of glaucoma under steroid treatment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 129-136.	1.0	3
1378	A cross-sectional study of sleep and depression in a rheumatoid arthritis population. <i>Clinical Rheumatology</i> , 2021, 40, 1299-1305.	1.0	17
1380	Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 215-228.	0.2	2
1381	Appraisal of the Antiarthritic Potential of Prazosin via Inhibition of Proinflammatory Cytokine TNF- α : A Key Player in Rheumatoid Arthritis. <i>ACS Omega</i> , 2021, 6, 2379-2388.	1.6	11
1382	Selected psychological factors and medication adherence in patients with rheumatoid arthritis. <i>Reumatologia</i> , 2021, 59, 90-97.	0.5	8
1383	Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. <i>Journal of Medical Economics</i> , 2021, 24, 299-307.	1.0	3
1384	Treatment expectations as a possible prognostic factor for DMARD response in rheumatoid arthritis: a prospective cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110158.	1.2	1
1385	Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110248.	1.2	4
1386	Quality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus. <i>Journal of Korean Medical Science</i> , 2021, 36, e109.	1.1	3
1387	Glucocorticoid and opioid use in rheumatoid arthritis management. <i>Current Opinion in Rheumatology</i> , 2021, 33, 277-283.	2.0	10
1388	Relationship between Tooth Loss and the Medications Used for the Treatment of Rheumatoid Arthritis in Japanese Patients with Rheumatoid Arthritis: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 876.	1.0	8
1389	Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study. <i>Modern Rheumatology</i> , 2021, 31, 796-802.	0.9	1

#	ARTICLE	IF	CITATIONS
1390	Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. <i>Cells</i> , 2021, 10, 323.	1.8	16
1391	The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission. <i>Modern Rheumatology</i> , 2022, 32, 68-73.	0.9	0
1392	A Review on Rheumatoid Arthritis Interventions and Current Developments. <i>Current Drug Targets</i> , 2021, 22, 463-483.	1.0	8
1393	Manifestaciones pulmonares de la artritis reumatoide, una revisi3n en tiempos de pandemia por SARS-CoV-2. <i>Revista Colombiana De ReumatologAa</i> , 2022, 29, S56-S65.	0.0	1
1394	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1239-1242.	1.0	12
1395	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. <i>Scientific Reports</i> , 2021, 11, 6918.	1.6	7
1396	Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review. <i>Rheumatology</i> , 2021, 60, 3540-3552.	0.9	5
1397	Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0248866.	1.1	21
1398	Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2021, 17, 101-108.	0.4	0
1399	Signalling and putative therapeutic molecules on the regulation of synoviocyte signalling in rheumatoid arthritis. <i>Bone and Joint Research</i> , 2021, 10, 285-297.	1.3	10
1400	TGFB1 (rs1800470 and rs1800469) variants are independently associated with disease activity and autoantibodies in rheumatoid arthritis patients. <i>Clinical and Experimental Medicine</i> , 2022, 22, 37-45.	1.9	4
1401	Application features of biological therapy in patients with autoimmune diseases. <i>Minerva Biotechnology and Biomolecular Research</i> , 2021, 33, .	0.3	0
1402	Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths. <i>European Journal of Rheumatology</i> , 2021, 8, 100-104.	1.3	1
1403	Natural medicine delivery from biomedical devices to treat bone disorders: A review. <i>Acta Biomaterialia</i> , 2021, 126, 63-91.	4.1	37
1404	Biologic Agents Preserve the C-2 Pedicle in Patients with Rheumatoid Arthritis: A Comparative Imaging Study Using Three-Dimensional Computed Tomography. <i>World Neurosurgery</i> , 2021, 149, e42-e50.	0.7	3
1406	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	1.8	12
1407	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>ReumatologAa ClAnica</i> , 2021, 17, 335-342.	0.2	3
1408	Evaluation of bone erosion in rheumatoid arthritis patients by high-resolution peripheral quantitative computed tomography scans: Comparison between two semi-automated programs in a three-dimensional setting. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 948-953.	0.9	3

#	ARTICLE	IF	CITATIONS
1409	Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms. <i>Frontiers in Immunology</i> , 2021, 12, 670398.	2.2	16
1410	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
1411	Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. <i>Vnitřní Lekarství</i> , 2021, 67, 195-200.	0.1	1
1412	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 335-342.	0.2	0
1413	Long-Term Risk of Autoimmune Diseases other than Systemic Lupus Erythematosus in Cutaneous Lupus Erythematosus-Alone Patients: A 10-Year Nationwide Cohort Study. <i>Dermatology</i> , 2022, 238, 92-100.	0.9	4
1414	Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1680-1689.	0.9	22
1415	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. <i>European Respiratory Review</i> , 2021, 30, 210011.	3.0	104
1416	Downregulation of miRĀ98Ā5p expression induces interleukinĀ6 expression in rheumatoid fibroblastĀlike synoviocytes. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1024-1031.	0.9	5
1417	An Efficient CNN for Hand X-Ray Classification of Rheumatoid Arthritis. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.1	9
1418	Lipidated Methotrexate Microbubbles: A Promising Rheumatoid Arthritis Theranostic Medicine Manipulated via Ultrasonic Irradiation. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1293-1304.	0.5	3
1419	BIological Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	0.6	4
1420	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	1.5	1
1422	Detection of Rheumatoid Arthritis Using a Convolutional Neural Network. <i>Advances in Intelligent Systems and Computing</i> , 2022, , 607-618.	0.5	0
1423	Exploring the role of monocyte chemoattractant protein-1 in fibroblast-like synovial cells in rheumatoid arthritis. <i>PeerJ</i> , 2021, 9, e11973.	0.9	1
1424	Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. <i>Clinical Rheumatology</i> , 2022, 41, 53-62.	1.0	7
1425	The use of biosimilars as a new approach to the treatment of rheumatoid arthritis. <i>Meditinskij Sovet</i> , 2021, , 112-121.	0.1	0
1426	Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117530.	0.3	6
1427	Nanotechnology as a Promising Platform for Rheumatoid Arthritis Management: Diagnosis, Treatment, and Treatment Monitoring. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121137.	2.6	5

#	ARTICLE	IF	CITATIONS
1428	Association Between the Extent of Periodontal Inflammation and the Severity of Rheumatoid Arthritis in Japanese Patients With Rheumatoid Arthritis. <i>International Dental Journal</i> , 2021, 71, 429-437.	1.0	7
1429	Synthesis and pharmacological evaluation of choroquine derivatives bearing long aminated side chains as antiviral and anti-inflammatory agents. <i>Bioorganic Chemistry</i> , 2021, 116, 105346.	2.0	2
1430	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	1.6	41
1431	Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis. <i>Pharmacotherapy</i> , 2018, 38, 172-180.	1.2	6
1432	Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases. <i>Methods in Molecular Biology</i> , 2016, 1371, 143-155.	0.4	4
1433	Interleukin 6. , 2014, , 1-8.		4
1435	Antirheumatika und Antiphlogistika. , 2018, , 423-434.		1
1436	Microbes, helminths, and rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101528.	1.4	7
1438	Education models and acquisition of biotherapies safety skills in chronic inflammatory rheumatism. <i>Education Therapeutique Du Patient</i> , 2019, 11, 10206.	0.5	2
1439	Characteristics of functional impairment in patients with long-standing rheumatoid arthritis based on range of motion of joints: Baseline data from a multicenter prospective observational cohort study to evaluate the effectiveness of joint surgery in the treat-to-target era. <i>Modern Rheumatology</i> , 2018, 28, 474-481.	0.9	10
1440	A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 161-167.	0.3	1
1442	A retrospective review of the persistence on <sc>bDMARD</sc>s prescribed for the treatment of rheumatoid arthritis in the Australian population. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1581-1590.	0.9	21
1443	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.5	30
1444	<i>Pneumocystis jiroveci</i> pneumonia in a patient taking Benepali for rheumatoid arthritis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224764.	0.2	2
1445	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	1.8	23
1446	The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. <i>Pan African Medical Journal</i> , 2021, 38, 183.	0.3	2
1447	Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. <i>F1000Research</i> , 2016, 5, 2019.	0.8	4
1448	Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. <i>Wellcome Open Research</i> , 0, 2, 13.	0.9	6

#	ARTICLE	IF	CITATIONS
1449	Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. Wellcome Open Research, 2017, 2, 13.	0.9	16
1450	Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report. World Journal of Clinical Cases, 2020, 8, 4527-4534.	0.3	11
1451	CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0128607.	1.1	19
1452	Pretreatment Prediction of Individual Rheumatoid Arthritis Patients'™ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers. PLoS ONE, 2015, 10, e0132055.	1.1	28
1453	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. PLoS ONE, 2015, 10, e0136982.	1.1	7
1454	Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0138543.	1.1	164
1455	Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach. PLoS ONE, 2016, 11, e0148791.	1.1	11
1456	A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. PLoS ONE, 2016, 11, e0152362.	1.1	20
1457	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. PLoS ONE, 2016, 11, e0153140.	1.1	19
1458	Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0160225.	1.1	42
1459	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. PLoS ONE, 2016, 11, e0161141.	1.1	32
1460	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0161727.	1.1	11
1461	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-Î± Inhibitors in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0163087.	1.1	43
1462	A Nationwide Survey on Patient's™ versus Physician's Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study. PLoS ONE, 2016, 11, e0166607.	1.1	16
1463	Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. PLoS ONE, 2016, 11, e0168369.	1.1	4
1464	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108.	1.1	41
1465	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. PLoS ONE, 2017, 12, e0171070.	1.1	30
1466	Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS ONE, 2017, 12, e0175281.	1.1	24

#	ARTICLE	IF	CITATIONS
1467	Factors associated with the risk of gingival disease in patients with rheumatoid arthritis. PLoS ONE, 2017, 12, e0186346.	1.1	7
1468	Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-. PLoS ONE, 2018, 13, e0194130.	1.1	65
1469	Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNF± therapy. PLoS ONE, 2018, 13, e0194693.	1.1	17
1470	BIOSIMILARS IN RHEUMATOLOGY. Nauchno-Prakticheskaya Revmatologiya, 2017, 54, 628-640.	0.2	19
1471	Rheumatoid arthritis in real clinical practice. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-IA») project. Sovremennaya Revmatologiya, 2019, 13, 25-30.	0.1	2
1472	Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats. Advanced Pharmaceutical Bulletin, 2016, 6, 617-625.	0.6	13
1473	Antimalarial Drugs-Induced Hepatic Injury in Rats and the Protective Role of Carnosine. Pharmaceutical Sciences, 2016, 22, 170-180.	0.1	13
1474	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Molecular Medicine, 2020, 12, e12476.	3.3	78
1477	Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 662-666.	0.9	19
1478	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment, 2018, 22, 1-280.	1.3	16
1479	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technology Assessment, 2018, 22, 1-294.	1.3	16
1480	Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data. Korean Journal of Internal Medicine, 2019, 34, 669-677.	0.7	13
1481	Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. Korean Journal of Internal Medicine, 2019, 34, 917-931.	0.7	20
1482	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms. Reumatologia, 2020, 58, 390-400.	0.5	8
1483	Effects of Conventional and Biological Drugs Used for the Treatment of Rheumatoid Arthritis on the Quality of Life and Depression. Eurasian Journal of Medicine, 2019, 51, 12-16.	0.2	11
1484	Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain. European Journal of Rheumatology, 2020, 7, 149-157.	1.3	4
1485	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. World Journal of Experimental Medicine, 2015, 5, 225.	0.9	21
1486	Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics. World Journal of Rheumatology, 2015, 5, 1.	0.5	8

#	ARTICLE	IF	CITATIONS
1487	The EANM guideline for radiosynoviorthesis. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 681-708.	3.3	23
1488	Antirheumatika und Antiphlogistika. , 2014, , 491-512.		0
1489	The potentiality of the IL-1 family and the IL-1 receptors as a disease marker and a therapeutic agent for periodontal disease. Journal of Japanese Society of Periodontology, 2014, 56, 272-280.	0.1	0
1490	Hospital and clinic cooperation for the treatment of rheumatoid arthritis in Okayama Prefecture, Japan. Okayama Igakkai Zasshi, 2014, 126, 209-215.	0.0	0
1491	Current Status of and Future Perspectives on Biologics in Rheumatic Diseases. Juntendo Medical Journal, 2015, 61, 573-579.	0.1	0
1493	Significant muscle loss following intramuscular corticosteroid injection used to treat active rheumatoid arthritis: a case report. Journal of Rheumatology and Orthopedics, 2015, 2, 2.	0.2	0
1494	Antirheumatika und Antiphlogistika. , 2015, , 501-517.		0
1496	Medicamenteuze therapie van reumatische aandoeningen. , 2015, , 275-287.		0
1497	Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. Open Journal of Rheumatology and Autoimmune Diseases, 2015, 05, 104-112.	0.1	0
1498	Rheumatoid arthritis: modern principles of diagnosing and treatment (reference review). Bukovinian Medical Herald, 2015, 19, 210-215.	0.1	0
1499	Reviewing Research on the Study of Rheumatoid Arthritis Model Treated by Pharmacopuncture in Korean Journals Objective. Journal of Korean Medicine Rehabilitation, 2015, 25, 37-49.	0.2	4
1500	Real World Data use and Applications in the Integrated Management of Rheumatic Disease. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000212.	0.2	0
1501	Overview of Biologic Therapies. , 2016, , 29-38.		0
1503	Tubal Pregnancy. , 2016, , 69-104.		1
1505	Rheumatoid Arthritis, Gout, and Spondyloarthritis in Foot and Ankle. , 2016, , 495-513.		0
1506	Pharmacotherapy of Rheumatoid Arthritis. , 2016, , 19-37.		1
1507	Antiphlogistika und Antiallergika. Springer-Lehrbuch, 2016, , 197-212.	0.1	0
1508	Interleukin 6. , 2016, , 686-692.		0

#	ARTICLE	IF	CITATIONS
1509	Corticosteroide. , 2016, , 421-426.		0
1510	Pentoxifylline in Rheumatoid Arthritis Treatment as an Adjuvant to the Synthetic Disease Modified Anti-rheumatic Drugs and Glucocorticoids. Pharmacologia, 2016, 7, 234-238.	0.3	0
1511	Pharmacological management of cardiovascular disease in patients with rheumatoid arthritis. , 2017, , 73-92.		0
1513	Practical Guide to Immunomodulatory Agents. Essentials in Ophthalmology, 2017, , 129-140.	0.0	0
1514	Medikamentöse Therapie entzündlich-rheumatischer Erkrankungen. , 2017, , 161-177.		0
1515	Erkennen von und Umgang mit Medikamentennebenwirkungen. , 2017, , 179-197.		0
1516	Regulation of Regulatory T Cell and B Cell Target Therapies. Journal of the Nihon University Medical Association, 2017, 76, 11-14.	0.0	0
1517	Rheumatologie. , 2017, , 469-497.		0
1518	Die rheumatoide Arthritis. , 2017, , 19-40.		0
1519	Corticosteroide. , 2017, , 425-430.		0
1520	Rheumatoide Arthritis. Pharma-Kritik (discontinued), 2017, 39, .	0.0	0
1522	SOME FEATURES OF THE RELATIONSHIP BETWEEN THE PATHOGENETIC MECHANISMS OF HYPOSALIZATION AND MARKERS OF INFLAMMATION IN RHEUMATOID ARTHRITIS AND SJOGREN'S SYNDROME. Bulletin of Problems Biology and Medicine, 2018, 1, 203.	0.0	0
1523	Visceral Leishmaniasis in the Mediterranean area. European Journal of Rheumatology, 2018, 5, 78-80.	1.3	0
1524	The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis. Sovremennaya Revmatologiya, 2018, 12, 120-123.	0.1	0
1525	Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis. Sovremennaya Revmatologiya, 2018, 12, 101-105.	0.1	2
1526	Antirheumatika und Antiphlogistika. , 2019, , 557-572.		0
1527	Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 703-708.	0.2	1
1528	Effect of Methanol Extract of <i>Gomphrena celsioides</i> on Chloroquine-Induced Hepatotoxicity and Oxidative Stress in Male Wistar Rats. American Journal of Molecular Biology, 2019, 09, 191-203.	0.1	0

#	ARTICLE	IF	CITATIONS
1529	The outcome of patients with rheumatoid arthritis: a cross-sectional study. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 5-9.	0.1	0
1530	Recommendations on the management of patients with axial spondyloarthritis. <i>Proceedings of the National Academy of Sciences of Belarus, Medical Series</i> , 2019, 16, 117-128.	0.2	0
1531	Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. <i>Pakistan Journal of Medical Sciences</i> , 2019, 35, 802-806.	0.3	1
1532	A paradigm shift in studies based on rheumatoid arthritis clinical registries. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 974-981.	0.7	2
1533	Role of physiotherapeutic factors in improving peripheral hemodynamics in patients with rheumatoid arthritis. <i>Medical Alphabet</i> , 2019, 1, 44-48.	0.0	1
1534	The interchangeability of original tumor necrosis factor- $\hat{\pm}$ inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis. <i>Sovremennaya Revmatologiya</i> , 2020, 14, 104-109.	0.1	0
1535	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	1.7	4
1536	Knockout of SLAMF8 Attenuates Collagen-Induced Rheumatoid Arthritis in Mice by Altering the Activity of TLR4/NF- $\hat{\rho}$ B Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1537	Arthritic, Metabolic, and Vascular Disorders. , 2020, , 230-238.		0
1538	Rheumatoid arthritis : a joint venture. <i>South African General Practitioner</i> , 2020, 1, 193-195.	0.0	0
1539	Rheumatic Diseases. , 2020, , 222-260.		0
1540	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy. <i>BMC Nephrology</i> , 2021, 22, 364.	0.8	2
1541	Consideraciones actuales de antimaláricos en la infección por SARS-COV-2 y su impacto. <i>Revista Colombiana De Nefrología</i> , 2020, 7, 19-20.	0.1	2
1542	Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. <i>Clinical Medicine</i> , 2020, 20, 551-559.	0.8	7
1544	The efficiency of biologic therapy in a group of patients with rheumatoid arthritis. <i>Journal of Medicine and Life</i> , 2015, 8, 79-84.	0.4	3
1545	Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment. <i>American Health and Drug Benefits</i> , 2015, 8, 354-60.	0.5	5
1546	Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations. <i>Journal of Orthopaedic Science</i> , 2015, 20, 951-7.	0.5	5
1547	Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. <i>American Health and Drug Benefits</i> , 2016, 9, 84-93.	0.5	36

#	ARTICLE	IF	CITATIONS
1548	MiR-19 suppresses fibroblast-like synoviocytes cytokine release by targeting toll like receptor 2 in rheumatoid arthritis. American Journal of Translational Research (discontinued), 2016, 8, 5512-5518.	0.0	18
1549	Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. American Health and Drug Benefits, 2017, 10, 42-49.	0.5	15
1550	Effects of polysaccharide fractions isolated from L. on the activity of phagocytic cells & humoral immune response in mice with collagen-induced arthritis: A comparison with methotrexate. Indian Journal of Medical Research, 2017, 145, 229-236.	0.4	2
1551	Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?. American Journal of Translational Research (discontinued), 2017, 9, 3758-3775.	0.0	3
1552	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. American Health and Drug Benefits, 2018, 11, 192-202.	0.5	9
1553	Lessons Learned From the RACAT Trial: A Comparison of Rheumatoid Arthritis Therapies. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 17-21.	0.6	1
1554	Circulating Inc-ITSN1-2 expression presents a high value in diagnosis of rheumatoid arthritis and correlates with disease activity. International Journal of Clinical and Experimental Pathology, 2017, 10, 10451-10458.	0.5	15
1555	Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis. Biomedical Reports, 2020, 13, 34.	0.9	0
1556	The Digital Way to Intercept Psoriatic Arthritis. Frontiers in Medicine, 2021, 8, 792972.	1.2	3
1557	Surgical treatment of wrist joint dysfunction in rheumatoid arthritis: A report of two cases. Modern Rheumatology Case Reports, 2021, , .	0.3	1
1558	Analytical Method Development and Validation of Etanercept by UV and RP-UFLC Methods. American Journal of Analytical Chemistry, 2021, 12, 493-505.	0.3	2
1559	Pharmakotherapie der rheumatoiden Arthritis: Vorteile und Limitationen. , 0, , .		0
1560	Automated Classification of Rheumatoid Arthritis, Osteoarthritis, and Normal Hand Radiographs with Deep Learning Methods. Journal of Digital Imaging, 2022, 35, 193-199.	1.6	18
1561	Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting. ReumatologĀa ClĀnica, 2022, 18, 567-573.	0.2	2
1562	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	0.9	3
1563	Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. CKJ: Clinical Kidney Journal, 2022, 15, 1373-1378.	1.4	6
1564	Identification of Risk Factors for COVID-19 Hospitalization in Patients With Anti-rheumatic Drugs: Results From a Multicenter Nested Case Control Study. Clinical Pharmacology and Therapeutics, 2022, 111, 1061-1065.	2.3	2
1565	Cytokines and Inflammation in Meniere Disease. Clinical and Experimental Otorhinolaryngology, 2022, 15, 49-59.	1.1	25

#	ARTICLE	IF	CITATIONS
1566	Nanotechnology-based strategies for effective delivery of phytoconstituents for the management of rheumatoid arthritis. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 2, 100061.	0.5	7
1567	Migration, Distribution, and Safety Evaluation of Specific Phenotypic and Functional Mouse Spleen-Derived Invariant Natural Killer T2 Cells after Adoptive Infusion. <i>Mediators of Inflammation</i> , 2021, 2021, 1-11.	1.4	3
1568	Rheumatoid arthritis: immunogenetic factors and immune therapies. , 2022, , 279-307.		3
1569	Interstitial lung disease and rheumatoid arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 21-40.	0.1	0
1570	Menopausal hormone therapy in rheumatoid arthritis. <i>Russian Journal of Human Reproduction</i> , 2022, 28, 149.	0.1	1
1572	Seasonal exacerbation of rheumatoid arthritis detected by big claims data analysis: A retrospective population study. <i>Modern Rheumatology</i> , 2023, 33, 46-53.	0.9	1
1573	New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology. <i>Frontiers in Immunology</i> , 2022, 13, 834247.	2.2	11
1574	Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study. <i>F1000Research</i> , 2022, 11, 187.	0.8	0
1575	Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2022, 49, 663-671.	1.0	2
1576	Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 79-88.	0.4	2
1577	Knockout of SLAMF8 attenuates collagen-induced rheumatoid arthritis in mice through inhibiting TLR4/NF- κ B signaling pathway. <i>International Immunopharmacology</i> , 2022, 107, 108644.	1.7	9
1578	The Efficacy of Sequential Biologic Agents in Refractory Rheumatoid Arthritis after Failure of Initial DMARD and anti-Tumor Necrosis Factor Therapy. <i>Rheumato</i> , 2021, 1, 22-30.	0.2	1
1579	Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5743.	1.0	3
1580	Jintiange Capsule Alleviates Rheumatoid Arthritis and Reverses Changes of Serum Metabolic Profile in Collagen-Induced Arthritic Rats. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6685-6706.	1.6	5
1581	Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events. <i>Rheumatology</i> , 2022, 61, 3567-3575.	0.9	9
1582	Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study. <i>BMC Rheumatology</i> , 2022, 6, 24.	0.6	1
1598	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	7
1599	Direct and indirect antiparasitic effects of chloroquine against the virulent RH strain of <i>Toxoplasma gondii</i> : An experimental study. <i>Acta Tropica</i> , 2022, 232, 106508.	0.9	4

#	ARTICLE	IF	CITATIONS
1600	Dexamethasone-Loaded Radially Mesoporous Silica Nanoparticles for Sustained Anti-Inflammatory Effects in Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2022, 14, 985.	2.0	12
1601	La polyarthrite rhumatoïde : prise en charge médicale à l'heure des biothérapies. , 2017, , 223-245.		0
1602	Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2955.	1.0	2
1603	The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1628-1637.	2.9	9
1604	Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs. <i>Rheumatology and Therapy</i> , 2022, 9, 1091-1107.	1.1	1
1605	NGHIÃŠN Cá»U Äá»C Äá»M SIÃŠU ÄM DOPPLER NÃ,NG LÃ»»CNG KHÃ»ŠP Cá» TAY Bá»†NH NHÃ,N VIÃŠM KHÃ»ŠP Dá»NG THÃ»P Äá»NGHÃ»Š ÄA KHOA NGHÃ»† AN. <i>Y Hoc Viet Nam</i> , 2022, 515, .	0.0	0
1606	Iguratimod Versus Salazosulfapyridine in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: Adjusted with Propensity Score Matching. <i>Modern Rheumatology</i> , 0, , .	0.9	0
1607	Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1196-1197.	0.5	3
1608	Deer Velvet Antler Extracts Exert Anti-Inflammatory and Anti-Arthritic Effects on Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes and Distinct Mouse Arthritis. <i>The American Journal of Chinese Medicine</i> , 2022, 50, 1617-1643.	1.5	13
1609	Current status and prospects of IL-6 targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	1.3	10
1610	Treatment Guidelines in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 679-689.	0.8	21
1611	Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1612	The effect of group-based cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: a randomized controlled trial. <i>Rheumatology</i> , 2023, 62, 1097-1107.	0.9	11
1613	Development and validation of equations for conversion from DAS28ESR and DAS28CRP to the SDAI in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 3697-3706.	1.0	0
1614	The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-12.	0.8	0
1615	Effects of RETN polymorphisms on treatment response in rheumatoid arthritis patients receiving TNF inhibitors and utilization of machine-learning algorithms. <i>International Immunopharmacology</i> , 2022, 111, 109094.	1.7	2
1616	In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113614.	2.5	38
1617	Molecular Modeling Guided Drug Designing for the Therapeutic Treatment of Rheumatoid Arthritis. <i>Cellular Microbiology</i> , 2022, 2022, 1-13.	1.1	2

#	ARTICLE	IF	CITATIONS
1618	National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wiener Klinische Wochenschrift, 2022, 134, 751-765.	1.0	1
1619	Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritis" (STARS) trial. Pediatric Rheumatology, 2022, 20, .	0.9	5
1620	Scientific Knowledge of Rheumatoid Arthritis: A Bibliometric Analysis from 2011 to 2020. Journal of Pain Research, 0, Volume 15, 2761-2772.	0.8	5
1622	IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. Frontiers in Immunology, 0, 13, .	2.2	12
1623	How to balance valuable innovation with affordable access to medicines in Belgium?. Frontiers in Pharmacology, 0, 13, .	1.6	6
1624	Risk of Liver Fibrosis in Methotrexate-Treated Patients: A Systematic Review. Cureus, 2022, , .	0.2	1
1625	Associations between clinical metrics of joint deformity, disease duration, disease activity, functional capacity, quality of life, pain, and fatigue in patients with rheumatoid arthritis. Clinical Rheumatology, 0, , .	1.0	1
1627	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 2023, 82, 3-18.	0.5	335
1628	Examining the safety of relaxed drug monitoring for methotrexate in response to the COVID-19 pandemic. Rheumatology Advances in Practice, 2022, 6, .	0.3	1
1629	Validation of traditional claims of anti-arthritis efficacy of trans-Himalayan snow mountain garlic (Allium ampeloprasum L.) extract using adjuvant-induced arthritis rat model: A comparative evaluation with normal garlic (Allium sativum L.) and dexamethasone. Journal of Ethnopharmacology, 2023, 303, 115939.	2.0	1
1631	Influencing factors in Tunisian Rheumatoid arthritis patients' Quality of life: burden and Solutions. Current Rheumatology Reviews, 2022, 19, .	0.4	0
1632	Prevalence and predictors of atlanto-axial subluxation in rheumatoid arthritis after 12-years' follow-up (ESPOIR Cohort). Rheumatology, 2023, 62, 2692-2699.	0.9	3
1633	Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting. Reumatología Clínica (English Edition), 2022, 18, 567-573.	0.2	0
1634	Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study. BMC Psychiatry, 2022, 22, .	1.1	6
1635	Use of Methotrexate in Girls and Women of Childbearing Age, Occurrence of Methotrexate-Exposed Pregnancies and Their Outcomes in Germany: A Claims Data Analysis. Clinical Drug Investigation, 2023, 43, 109-117.	1.1	3
1636	Outcomes Following Adalimumab Bio-originator to Biosimilar Switch: A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. Rheumatology and Therapy, 0, , .	1.1	1
1637	Performance Analysis of CNN and Quantized CNN Model for Rheumatoid Arthritis Identification Using Thermal Image. Communications in Computer and Information Science, 2023, , 135-150.	0.4	0
1638	Telotristat Etiprate alleviates rheumatoid arthritis by targeting LGALS3 and affecting MAPK signaling. Intractable and Rare Diseases Research, 2023, 12, 45-57.	0.3	2

#	ARTICLE	IF	CITATIONS
1640	Methylation of receptor activator of nuclear factor kappa ligand (RANKL) gene in rheumatoid arthritis patients. <i>Egyptian Rheumatologist</i> , 2023, 45, 171-176.	0.5	0
1641	Improvement of the psycho-emotional state and cytokine profile of patients with rheumatoid Arthritis and hepatic steatosis after therapy with thioctic (lipoic) acid and methotrexate. <i>Kazan Medical Journal</i> , 2023, 104, 13-19.	0.1	0
1642	Rheumatoid Arthritis " Common Origins, Divergent Mechanisms. <i>New England Journal of Medicine</i> , 2023, 388, 529-542.	13.9	106
1643	MTHFR c.665C>T and c.1298A>C Polymorphisms in Tailoring Personalized Anti-TNF± Therapy for Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4110.	1.8	2
1644	Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2023, 62, 2652-2660.	0.9	9
1645	Advanced therapies in rheumatoid arthritis. , 2023, , 181-205.		0
1646	Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab. <i>Rheumatology International</i> , 2023, 43, 881-888.	1.5	1
1647	Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. <i>Pharmaceuticals</i> , 2023, 16, 465.	1.7	2
1648	Robust analyses for radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2023, 9, e002543.	1.8	0
1649	Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1650	Current Prospects in Rheumatoid Arthritis: Pathophysiology, Genetics, and Treatments. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2023, 18, .	0.4	1
1651	Development of an ultrasound set for early diagnosis of rheumatoid arthritis: First steps. <i>Revista Colombiana De ReumatologÃa</i> , 2023, , .	0.0	0
1652	Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study. <i>Rheumatology International</i> , 0, , .	1.5	1
1660	A SENS Score of Rheumatoid Arthritis Detection Using Customized Convolutional Neural Network. <i>Lecture Notes in Networks and Systems</i> , 2023, , 643-652.	0.5	0